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Introduction
Nowadays, cancer is still a second leading cause of death after cardiovas-
cular disease in the world [1]. One of the main factors that lead the failure of
cancer therapy is related to the fact that little is known about the interaction
of cancer cells with microenvironment. Indeed, as hypothesized in the ”seed”
and ”soil” theory by Paget over a century ago, tumor progression is deter-
mined not only by tumor cells but also by the surrounding stromal milieu
[2]. For these reasons in the last years, increasing attention is focused on
the importance of tumor microenvironment in an effort to develop successful
strategies in cancer disease treatment [3], [4]. In traditional two-dimensional
in vitro models the absence of 3D architecture generates misleading and con-
tradictory results [5]. Hence emerges the need to have an in vitro versatile
platform that closely recapitulates pathophysiological features of the native
tumor tissue and its surrounding microenvironment [5].
In this PhD thesis a microtissue precursors (µTP) assembling strategy,
recently published [6], was used and translated to produce 3D tumor engi-
neered models composed by tumor and/or stromal cells. In contrast with
the classical spheroid model, the µTP we proposed presents the production
of extracellular matrix directly synthesized by stromal cells.
First of all, in the chapter 1 a stat of art overview was presented which
highlights the importance of tumor microenvironment in cancer research,
the existing models for studying tumor development and the nanotechnology
contribution in cancer treatment. Then the chapter 2 is focalized on the
realization of stromal microtissues fabricated seeding normal or activated
fibroblasts on microporous beads, in order to monitor their dynamic evolution
in terms of metabolic activity, mechanical properties and ECM composition.
In particular it is demonstrated how the microtissue configuration is able to
keep phenotypic differences between normal and activated fibroblasts in all
the aspects investigated compared to the classical 3D spheroidal model. In
7
the chapter 3 the cross talk between epithelial tumor and the surrounding
stroma in a microfluidic device is investigated. Thanks to the combination
of 3D microtissues with microfluidic technology, it is possible to detect in
real time the modification occurring at cellular and ECM level during the
activation period.
In the second part of work, the tumor microtissue model is validated as
a potential drug-screening platform. In particular, in chapter 4 a commonly
drug used in chemotherapy (Doxorubicin) is tested in order to detect the dif-
ference in chemoresistance between microtissues and spheroid models, both
in monoculture and coculture. Finally, a stimuli-responsive nanoparticles
are tested on normal and tumor 3D heterotypic microtissues to demonstrate
their significant selectively. At last, the microtissue system may be a useful
in vitro screening tool for testing innovative approaches of drug delivery, re-
ducing expensive and time-consuming protocol nowadays used in preclinical
studies.
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Chapter 1
State of Art
1.1 Tumor microenvironment
Nowadays, cancer remains a leading cause of death. Thus, it is not surpris-
ing that the majority of drug candidates in development today are aimed at
stalling or eliminating cancer. However, cancer drug development is costly, as
it suffers from a very low success rate. Despite significant progress in clinical
research in recent years resulting in the development of more specific anti-
cancer drugs such as nanoparticles or monoclonal antibodies such as imatinib,
trastuzumab, crizotinib and vemurafenib, their activity remains poor with
no evidence of tumor withdrawing [7]. The high heterogeneity and plastic-
ity of this ever-changing dynamic desease make it difficult to develop widely
applicable drugs with low side effects. There is extensive evidence demon-
strating the importance of tumor microenvironment on cancer progression
and treatment outcome [8]. Infact, tumor microenvironment (TME) plays
an important role in regulating the behavior of cancer cells to invade and
metastasize and poses multi-faceted barriers including biological, chemical
and physical hindrance to drug transport and actions. These barriers are
highly dynamic so their interactions and relative significance with respect
to drug delivery and therapeutic efficacy vary drastically depending on the
cancer type, stage and organs [9]. Indeed, in many tumor types, such as pan-
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creatic and breast tumors, these barriers can become insurmountable, often
leading to therapy failure [10]. To this end, the specific cross-talk between
a given cancer and its stroma will have to be defined for each cancer type
in order to achieve effective therapeutic targeting [8]. Carcinomas comprise
the majority of all solid tumors, and their malignancy is driven not only
by the genetic transformation of epithelial cells, but also by the remodeling
of contiguous stromal tissue to foster growth, metastasis and therapy resis-
tance [11]. Among carcinomas, breast cancer is the most frequent cancer
in woman together with colorectal and ovarian cancers. The systemic out-
growth and spread of the cancer cells through a process known metastasis is
the main cause of deaths in these patients. The development of breast cancer
involves the progression via a series of intermediate hyperplastic lesions with
and without atypia (atypical ductal hyperplasia, atypical lobular hyperplasia
and usual ductal hyperplasia) followed by subsequent evolution into in situ
carcinoma, for example ductal carcinoma (DCIS) and lobular carcinoma in
situ (LCIS), invasive carcinomas and metastatic cancers (Fig. 1.1 [12]). In
atypical hyperplasia, the breast cells are abnormal in number size, shape, ap-
pearance, and growth pattern that may be seen as an excessive growth of cells
of the ducts (atypical ductal hyperplasia) or the cells of the lobules (atypical
lobular hyperplasia). DCIS is thought to be a precursor of invasive ductal
carcinoma, in which tumor cells are confined to the lumen of the mammary
duct [12]. Seventy-five to 80% of invasive breast carcinomas are categorized
as invasive ductal carcinoma (IDC), which is the progression of a primary
tumor from within the breast duct to an invasion of surrounding tissue by
penetrating through the basement membrane of the duct. During cancer
progression from DCIS to IDC, the tumor cells invade the reactive stroma.
Although the ductal epithelium and the underlying myoepithelial cells are
separated from the surrounding connective tissue by a basement membrane
in both normal and tumor carcinoma in situ, the basement membrane in
DCIS, although intact, is altered.
LCIS, instead, is characterized as abnormal proliferation of acinar cells
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in terminal ductal lobular units [13]. Invasive lobular carcinoma (ILC) is the
invasive growth of cancer cells that originate in the lobules and penetrate the
surrounding breast tissue [14]. Furthermore, gene expression changes occur
in all cell types during breast tumor progression [15].
In breast cancer, dynamic changes in the microenvironment are character-
ized by formation of tumor stroma containing abundant fibrous components
as well as by active recruitment of inflammatory cells during the progression
from mammary gland hyperplasia to adenoma formation and eventually to
cancer [16]. It is becoming increasingly clear that the inflammatory changes
occurring in the tumor microenvironment are closely linked with initiation,
promotion and progression of tumorigenesis, and thereby have become the
focus of intense research [16].
Figure 1.1: Schematic presentation of breast cancer progression accompanied
with stromal cells [12].
Cellular components of the tumor microenvironment
Human tumors encompass various cell types whose functions and fate are
further differentially influenced by multiple chemical, physical and biologi-
cal factors present in the microenvironment [7]. In tumors, heterogeneous
cancer cell populations coexist with non-mutated progenitor cells (epithelial
cells) and stromal cells that support the TME. These include fibroblasts and
immune cells, as well as endothelial cells and smooth muscle cells that form
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blood vessels and provide nourishment to the tumor. In their dysfunctional
state, fibroblast and immune cells produce chemokines and growth factors
that stimulate cancer cell growth and invasion and can recruit other cells, in-
cluding mesenchymal stem cells (MSCs) that replenish cells in the tumor [3].
The immune system plays dual roles in tumor development and progression.
In addition to the above studies indicating that immune cells can promote
tumor development, other studies have reported that adaptive immune cells,
for example B and T lymphocytes, may inhibit later stages of cancer de-
velopment by affecting growth and/or dissemination of primary tumors [17].
In addition to the cellular component, the extracellular matrix (ECM) and
secreted extracellular molecules act in autocrine and/or paracrine manners
to support/sustain tumor development (Fig. 1.2).
Figure 1.2: The tumor microenvironment: schematic illustrating cellular
components (cancer cells and variuos stromal cells) coexisting in the tu-
mor microenvironment and extracellular components secreted by the cellular
components of the tumor [7].
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Fibroblasts
As the predominant cells in stroma, fibroblasts are responsible for the elab-
oration of the most connective tissue components in the ECM, including
collagens and structural proteoglycans, as well as various classes of prote-
olytic enzymes, their inhibitors and various growth factors [17]. In normal
tissues, fibroblasts produce different collagen subtypes (type I, III and V)
and fibronectin, and contribute to the formation of the basement membrane
by secreting type IV collagen and laminin. They continuously remodel the
ECM through a dynamic process of ECM protein production and degra-
dation by matrix metalloproteinases (MMPs) and other proteases and are
responsible for the overall architecture of tissues. The turnover is, however,
well regulated and restrained [18]. On the other hand, cancer-associated fi-
broblasts (CAF) have phenotypes that are significantly different from normal
fibroblasts. Like fibroblasts in wounds, CAF exhibit a higher proliferation
rate, express α-smooth muscle actin and variants of fibronectin, which are
involved in cell contraction and wound closure. However in tumors, unlike
fibroblasts in wounds, CAFs do not revert back to their inactivated state, or
undergo apoptosis.
The so-called CAF or myofibroblasts, peritumoral fibroblasts or reactive
stromal cells, play a determinant role in malignant progression of cancer and
represent an important target for cancer therapies [19]. CAF are known
to supply many inflammatory mediators including a variety of cytokines,
growth factors, tissue remodeling enzymes such as matrix metalloproteinases
(MMPs) and ECM components, all of which modulate the TME to aid the
active mobilization of the inflammatory cells [16]. CAF also secrete growth
factors (transforming growth factor beta TGF-β, hepatocyte growth factors
HGFs, insulin-like growth factors IGFs) and chemokines (monocyte chemo-
tactic protein 1 and interleukin 1) that facilitate proliferation and invasion of
cancer cells. In addition, CAF produce MMPs, mostly MMP-9 and MMP-2,
and other matrix-modifying enzymes, including urokinase-type plasminogen
activator (uPA) that degrades the ECM and support tumor invasion and
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metastasis [3].
Smooth muscle α-actin (α-SMA) is the most common marker used to
identify myofibroblasts together with PDGF receptor (PDGFR) α/β [20].
PDGF plays an important role in the regulation of fibroblasts and pericytes
modulating tumor progression. Moreover it has a limited autocrine role in
tumor cell replication, but it is a potential player, in a paracrine fashion, in
tumor stroma development. PDGf induces CAF proliferation and possibly
recruiting CAF indirectly by stimulation of TGF-β release from macrophages
[21]. In breast cancer, high stromal PDGF β -receptor expression was signif-
icantly associated with high histopathological grade, estrogen receptor neg-
ativity and high HER-2 expression. Based on animal model studies, PDGF
receptor activation in stromal cells have also been shown to control tumor
drug uptake and tumor oxygenation [22].
Immune cells
In addition to fibroblasts, immune cells are abundant cells in tumor tissue.
Among immune cells, tumor-associated macrophages (TAMs) have a central
role in tumor growth [23]. TAMs derived from differentiated monocytes that
have been recruited to the reactive stroma in response to tumoral chemotactic
factors or from resident macrophages. There are two major lines connecting
TAMs and cancer: 1) accumulation of TAMs in tissues of chronic inflam-
mation apparently promotes cancer initiation and progression and 2) a high
density of TAMs in tumor tissues often correlates with poor prognosis for
cancer patients. It is well accepted that TAMs are required for tumor cell
migration, invasion and metastasis formation [24]. However the best charac-
terized pro-tumoral function of TAMs relates to their pro-angiogenic capac-
ities by secretion of specific pro-angiogenic factors (VEGF, IL-1 β, TNF- α)
or indirectly through the release of MMP-9 [24].
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Endothelial cells
Besides interactions with TAMs and CAF, the interplay of tumor cells with
endothelial cells (ECs) is also of pivotal importance for tumor progression
and the development of metastasis. It is generally assumed that cancer cell
migration through connective tissue is too slow and undirected to account
for the quick spreading and metastasis formation seen in many tumors, and
that cancer cells spread much more quickly and efficiently via lymph or blood
vessels to distant sites. The endothelium and the basement membrane con-
stitute a strong physical barrier, hence the process of intravasation is po-
tentially time-consuming and rate-limiting in metastasis development [24].
Signaling cross-talk between cancer cells and ECs may involve up-regulation
of adhesion molecule expression by the endothelium as well as by tumor cells,
reorganization of the acto-myosin cytoskeleton and Src-mediated disruption
of endothelial VE-cadherin-β-catenin cell-cell adhesions [24].
Abnormalities of tumor ECM
Extracellular matrix (ECM) is a fundamental component of the tumor mi-
croenvironment that acts bidirectionally, both affecting and being affected by
tumor cells. The ECM not only plays an important role in providing support
to tissues, but also directs a diverse set of functions in individual cells [25].
In particular, ECM can act as a scaffold for cell migration, a reservoir for
cytokines and growth factors and a signal through receptor binding [16]. Al-
though the ECM prevents tumor cells from invading the surrounding tissues
its remodeling ECM is crucial in order to promote this phenomenon. Nu-
merous factors are involved in this process, including integrins, lysyl oxidase
(LOX) and MMPs. Integrins are a family of heterodimeric, transmembrane
glycoproteins, consisting of one α and β unit. Each family member binds
multiple ECM ligands which activates intracellular signaling pathways [26].
Members of the LOX family are secreted by cancer and stromal cells in re-
sponse to hypoxia and modify the ECM [26]. In particular, LOX cross-links
newly synthesized collagen and its expression and activity are elevated in
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response to increased collagen deposition [27]. MMPs are a family of prote-
olytic enzymes which are synthesized both by tumor and peritumoral stromal
cells (CAF) and their primary function is degradation of protein in the ECM
and release growth factors and cytokines that reside in the ECM [26]. They
can be considered the most important proteolytic enzyme for connective tis-
sue dissolution [28]. Through their proteolytic activity, MMPs are implicated
in cancer invasion and metastasis with different classes of MMPs being asso-
ciated more frequently with cancer of varying origin [28]. Their expression
is often highly up-regulated in many solid tumors, and the sustained pres-
ence of these proteases coupled with increased ECM synthesis and secretion,
leads to the progressive destruction of normal ECM and its replacement by
tumor-derived ECM. MMP degradation of the ECM not only facilitates cell
movement but also generates numerous bioactive cleaved peptides and re-
leases growth factors and chemokines that are contained within the ECM
[27]. MMP-1 (collagenase-I), the first MMP discovered in 1962, is one of
the proteases responsible for degrading fibrillar collagens. High-expression of
MMP-1 has been linked to cell invasion in vivo; therefore targeting MMP-1
is often used as a strategy for attenuating cell invasion. Other members of
MMP family, such as gelatinases MMP-2 and MMP-9, degrade collagen IV,
which is the major component of basement membranes and is also found
in stromal ECM [29]. These types of MMPs have focused great attention
because they are overexpressed in a variety of malignant tumor and their
expression and activity are often associated with tumor aggressiveness and
a poor prognosis [30]. Elevated levels of gelatinases are found in breast,
brain, ovarian, pancreas, colorectal, prostate and melanoma [30]. Further-
more, a differential regulation of MMP-expression can be found in tumors of
different grades of malignancy in a mouse transplantation model in vivo as
demonstrated by Mueller et al. (2002).
The abnormal structure and function of tumor stroma is largely at-
tributed to the up-regulation of matrix remodeling molecules such as the
transforming growth factor β (TGFβ) and some matrix components such as
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fibronectin (FN) and hyaluronic acid (HA). These abnormalities, collectively
known as desmoplasia, refer to the formation of a dense ECM characterized
by increased levels of total fibrillar collagen, fibronectin, proteoglycans (PGs)
and tenascin C and it is associated with activation of angiogenic programs.
In fact, desmoplastic response has been demonstrated to be associated with
more aggressive and invasive cancer and worse prognosis in several types of
cancer such as papillary microcarcinomas, breast cancers and rectal cancers.
FN plays an important role in the formation of the pre-metastatic niche. In
particular, FN binds collagen and regulates collagen fibril organization. The
dynamic and reciprocal relationship between collagen and FN plays a role in
tumor progression [31]. Fishbach et al. (2005), reported that increased con-
centration of FN in tumors have been linked to enhanced malignant capacity
of tumors [32]. Furthermore HA is another main component of the tumor
microenvironment and has thus become an increasingly important target for
cancer therapy [16]. It is a large glycosaminoglycan known to be up-regulated
in the extracellular space of tumor and thought to impede drug delivery by
functioning as an immobile, gel-like phase due to negative charge repulsion
and water sequestration. For instance, increased secretion of HA by CAF
is commonly observed in pancreatic cancer and it is known to promote tu-
mor growth. This could be caused by increased interstitial pressure (IFP)
due to water molecule retention [33]. Similar to other ECM molecules, HA
degradation products have the ability to induce specific gene expression pro-
grams for proteases and cytokines that are necessary for inflammation and
matrix remodeling [16]. ECM deposition and desmoplastic response differ
significantly among various cancer types, indicating different mechanisms of
cancer development and progression. Desmoplasia may contribute to an in-
crease in tumor density that, as a tumor grows in the confined space of the
host tissue, results in the generation and accumulation of mechanical forces
among the components of the tumor microenvironment. Finally, desmoplasia
limits the available space for transport in the tumor interstitial space, which
prevents homogeneous penetration of therapeutic agents. High collagen and
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cellular densities reduce the size of the pores of the tumor interstitial space
and as a result the resistance to interstitial fluid flow increases. This, in turn,
further enhances the uniform elevation of the IFP and renders diffusion the
dominant transport mechanism in the tumor interior [10].
1.1.1 Cancer cell invasion in tumor microenvironment
Tumor cell migration is a crucial prerequisite for metastasis and has been
regarded largely as a mechanical process dependent on the expression of
adhesion molecules and matrix degrading enzymes [24]. This phenomenon
involves dynamic and drastic changes in the adhesion structures, also called
the focal complexes, which are assembled by membrane, associated recep-
tor and other signal-relaying molecules. The drastic changes in cell adhesion
state during migration and invasion are fulfilled by actin polymerization that
facilitates its disassembly and reorganization that confers the motility of the
cells [23]. As outlined by Branek et al. (2010) [34], the architecture and
composition of the TME in terms of structural and biochemical properties
of the ECM (fiber network, morphology collagen content, fiber thickness,
extent of intrafibrillar crosslinks and the ratio mesh size-diameter of the mi-
grating cell) determines the degree of resistance the moving of cells [24].
Epithelial-stromal interaction plays a crucial role in tumor formation and
progression. Therefore, due to the increased stroma associated with breast
tissue density, increasing collagen density in the mammary gland promotes
tumorigenesis or stromagenesis [35]. Stromagenesis is induced by neopla-
sia, accompanies tumor development and can be sorted into three distinctive
phases: normal, primed, and activated [36]. Recent studies indicate that
the TME can profoundly affect tumorigenesis even at the earliest stages of
neoplasia prior to breaching the epithelial basement membrane barrier [37].
The first step in metastasis is the migration of cancer cells away from the
primary tumor, a process called tumor invasion (Fig. 1.3). In vivo cancer
cells can invade tissue individually as single cells in elongated, mesenchymal
or rounded, amoeboid modes after cell-cell junctions were abandoned. Al-
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ternatively, cancer cells retain cell-cell junctions and migrate collectively as
cohesive multicellular units into the peritumoural stroma [38].
Figure 1.3: Summary of tumor progression and invasion [39].
Tumor cells often localize near dense collagen and promote a desmoplas-
tic response, followed by tumor growth and expansion of the collagen matrix
leading to matrix reorganization to help facilitate local invasion [40]. In solid
epithelial tumors or carcinomas, invading cells cross the basement membrane
(BM), a natural barrier between the epithelium and the stroma and come into
direct contact with the interstitial/stromal ECM. These migrating activated
epithelial cells can trigger the activation of stromal cells, either directly or
by means of paracrine signals, resulted in a ”primed” or ”activated” stroma
[29]. Finally metastasizing cells migrate through the stroma to reach blood or
lymph vessels, where they can be carried to other organs [39]. In vitro stud-
ies have identified different intrinsic factors regulating migration of cancer
cells. Tumor cells are able to migrate individually or collectively depending
on typology of cell. In addition to intrinsic factors, the TME plays a sig-
nificant role in determining cancer cell migration mode and morphology. In
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human epithelial cancers such as breast and colorectal cancers, invasive cells
are typically observed to migrate collectively. Invading cells often display
characteristic Epithelial to Mesenchymal Transition (EMT) markers, such
as down-regulation of E-cadherin and up-regulation of Vimentin, and lose
some epithelial characteristics, such as apical-basal polarity. During tumor
progression, the stroma also undergoes profound changes.
The content and distribution of collagen in cancer tissue are different from
the corresponding normal tissue due to remodeling of the ECM during malig-
nant process. In particular, CAF deposit abundant amounts of fibrillar ECM
molecules including collagen I and FN. These ECM compositional changes
entail structural and mechanical alterations of the ECM. For example, CAF
mediate the partial unfolding of FN, which increases both the stiffness of
individual FN fibers and their ability to bind other ECM molecules such
as glycosaminoglycans (GAGs) and collagen. Along with elevated collagen
crosslinking and GAG concentration, these pronounced changes in ECM den-
sity and intermolecular interactions globally enhance tumor stiffness with
direct consequences for tumor progression [41]. Under normal physiologic
conditions, fibroblasts are in an inactive quiescent state, have a low pro-
liferative index and only secrete factors needed to maintain normal tissue
homeostasis. Tumor cells are unable to overcome the constraints imposed by
the normal microenvironment unless stroma itself undergoes a series of al-
terations. Changes in normal stromal fibroblasts produce a ”primed” stroma
that promotes tumor growth and invasion during the earliest stages of stro-
magenesis [37]. Activation of stromal cells into CAF has many consequences
for tumor development, progression and cancer metastasis. CAF have been
reported to produce a variety of growth factors and cytokines that promote
tumor progression. Secreted stroma-derived factors include TGFβ1, HGF,
EGF, VEGF, stroma-derived factor-1, basic FGF and pro-inflammatory cy-
tokines CXCL14, IL-1, IL-6 and IL-8.
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1.2 Existing models for studying tumor de-
velopment and drug testing
Tissue engineering is a multidisciplinary field aimed at creation of human tis-
sues or organs by hybridizing therapeutic cells with biomaterials and other
conditions that facilitate cell growth and differentiation followed by tissue
morphogenesis. Apart form the current mainstream applications of tissue
engineering in therapeutics for repairing or replacing diseased tissues or or-
gans, namely for the purpose regenerative medicine, the engineered tissues
can also be potentially used for cancer drug evaluation. Drug evaluation is
generally assessed in terms of three key areas: drug delivery methods, drug
efficacy and drug toxicity. These parameters are important because it is im-
perative to develop an efficient drug delivery method that can maximize drug
efficacy while minimizing toxic side effects [42]. One of the most immediate
uses for tissue-engineered systems is as a tool for biologists and physicians
to create a more clinically accurate ex vivo physiology of human tissues.
Below it is described current state of in vivo and in vitro models.
1.2.1 In vivo models
One way to better replicate the biological complexity of human tumor growth
is to study human cancer within an animal model. This provides tumor cells
with many of the 3D microenvironmental cues that are missing during mono-
layer growth. The most common mouse model employed in drug testing for
solid tumors is the subcutaneous human tumor xenograft. In this model,
human tumor cells are implanted just beneath the skin of immunodeficient
mice, and a few days or weeks are allowed for initial tumor growth before
drug candidates are administered. A great advantage of this method is the
capability to transplant both cancer tissue and surrounding stroma to mimic
the complexity of the human tumor microenvironment. Unfortunately, many
drugs appear promising when tested in xenografts, but several studies involv-
ing a variety of tumor types have found a general lack of correlation between
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the human tumor xenograft response data and the results of phase II clinical
trials [43] (Fig. 1.4). The reasons can be most likely due to murine origin
rather than human of TME, which implies subtle but important changes
that impact tumor cell behavior. Obvious limitations of animal models that
preclude their use in large-scale drug discovery programs include their unsuit-
ability for high-throughput drug screening owing to considerations of space,
time and cost. Another major challenge is how to observe tumor growth or
regression over the course of a treatment, for example at weekly intervals.
The assessment of treatment efficacy can be reliably performed only at the
end of the trial, when animal is sacrificed [44].
Figure 1.4: In vitro and in vivo models [45].
1.2.2 In vitro models
The complexity of TME in vivo makes difficult to study manifold phenomena
like tumor invasion because it is necessary to isolate and control individual
stimuli. The requirement for such control has led to the development of in
vitro assays that mimic aspects of the in vivo tissue. In vitro testing of
anticancer drugs typically involves growing cancer cell lines as monolayers
on Petri dishes and using high-throughput screening procedures to evaluate
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drug efficacy. In 2D cells are not able to organize into tissue-like structures
since they lack the tridimensionality of the surrounding microenvironment
[46]. For this reason, the monolayer culture has remained a poor predictor
of whether a given drug will ultimately yield clinical benefit. These cells,
therefore, may not be representative of the tumor as a whole and are espe-
cially susceptible to therapies that target rapidly dividing cells. Perhaps the
most dramatic alterations occur, however, because of the removal of the cells
from their native microenvironment, including the ECM, soluble signals, 3D
architecture, stromal cells, and irregular microvasculature that surround the
tumor cells in vivo. These stromal elements affect many different aspects
of cancer cell behavior, including the cell’s proliferation rate and resistance
to drug-induced apoptosis [43]. To avoid these experimental inconsistencies,
it is essential to develop models with a higher degree of complexity with
retaining the reproducibility and the capacity of cellular level imaging [45].
Recent advances in this field include the incorporation of multiple cell types
and ECM proteins into 3D models to recapitulate the structure, organization
and functionality of live tissue in situ [47].
In recent years there are increasingly more attempts to create three-
dimensional biomimetic engineered tissue models that are expected to better
fulfill the role in drug evaluation. These attempts are aimed at recapitu-
lating some of the important human native tissue structures and functions
so that the response to therapeutic administrations may be predicted more
accurately in an in vitro setting. This paradigm shift from two dimensional
cell-based model to 3D tissue model is essential because cell cultured on cell
culture plates or microwells are incapable of providing a realistic model of the
intercellular environment [42]. Tumor cell spheroid and scaffold-based mod-
els are the most popular 3D culture systems that have been concomitantly
developing since the 1970s [23]. In 3D tumor models, cells are cultured as ag-
gregates (spheroids), are grown on 3D scaffold materials or are embedded in
gels. In every case, cells in a 3D environment behave fundamentally different
from cells in monolayer culture, as cell-matrix interactions trigger signaling
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pathways and cellular responses in 3D, which may not be observed in 2D [47].
Moreover, biochemical nature of cell-cell and cell-extracellular matrix con-
tacts and the structural organization of cells differ significantly between two
dimensional and three dimensional cultures, which could also be responsible
of augmented drug resistance of cancer cells in three dimensional culture [48].
Human spheroid
By far, the most widely used 3D model is the human tumor spheroid, a small,
tightly bound cellular aggregate that forms in the absence of cell substrate
adhesion. These cellular aggregates can range in size from 20 µm all the
way up to 1 mm in diameter, depending on the cell type and growth condi-
tions. Spheroids have been widely used in cancer research because the 3D
architecture and extensive cell-cell contacts provided by spheroid growth ap-
pear to better mimic the in vivo cellular environment than two-dimensional
monolayer cultures. Spheroids also exhibit many of the biological properties
of solid tumors, including cell morphology, growth kinetics, gene expres-
sion and drug response. Spheroid formation can be induced by a variety of
different techniques including hanging drop method, liquid-overlay cultures
and dynamic bioreactors. In the hanging drop method, cells form spheroids
within small droplets of cell suspensions (approximately 20-50 µL). Due to
the surface tension, liquid can maintain droplets when the lid is inverted
and cells settled at the bottom of the droplet, air-liquid interface [9]. A
simpler method for spheroid production involves liquid overlay of a cell sus-
pension over a non-adherent surface, such as agar-coated plates. Spheroids
can also be formed by culturing in spinner flasks or bioreactors, which can
provide dynamic conditions preventing cell-substrate contact and promoting
cells to form aggregates by either stirring or rotating bioreactors. The earliest
method employed in cancer biology, that is widely used today, is spinner flask
culture, where fluid turbulence prevents attachment and promotes cellular
aggregation. This system can produce large numbers of relatively consistent
spheroids, but they both require specialized equipment and additional pro-
27
cessing steps when used for drug testing. One of the major uses of human
tumor spheroids has been as a preclinical screening tool for anticancer drug
candidates, including traditional cytotoxic drugs, antibody-based therapies,
and various experimental therapeutic approaches. Cancer cells from a wide
variety of tumor types consistently display greater resistance to anticancer
drugs when grown within spheroids, compared to monolayer controls, repli-
cating what is often observed in the clinical settings. The increased chemore-
sistance in spheroids compared to monolayer cultures may be explained in
part by increased cell-cell contact, 3D cellular architecture, enhanced depo-
sition of tumor-derived ECM within the spheroid, a lower overall cell pro-
liferation rate, or a combination of these factors. Although a 3D system
with cancer cell lines cannot recapitulate the genetic heterogeneity found in
tumors, modeling cellular heterogeneity can be achieved to a certain degree
with heterotypic multi-cellular models. Examples of 3D co-culture models
are formed by tumor cells and fibroblasts or a further increase in the com-
plexity of the model can be achieved by implementing endothelial cells [7].
3D heterotypic tumors cultures enable tumor cells to establish cell-cell and
cell-ECM interactions, which are important elements in tumor signaling and
which modulate tumor responses to therapeutic agents. Spheroids are conve-
nient and relatively simple techniques to simulate in vivo solid tumor. Cells
within spheroids display cell-cell interactions and produce in vivo tumor-like
biochemical responses compared to 2D cell culture [9]. In spite of these ad-
vantages, the lack of interstitial fluid dynamics, which is highly relevant to
drug transport within the TME, is one of the major limitations. It is there-
fore likely that the diffusion of most drugs, which are typically much larger
than oxygen and carbon dioxide molecules, will be limited within spheroids
as well [43].
Tumor cells embedded in gels
Considering that microenvironment controls tumorigenesis, ECM analogs
have been introduced as cell culture systems in order to embed cells in a 3D
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context and display the appropriate physical, chemical and mechanical cues
for cell fates. Because spheroid culture only succeeds in mimicking a small
part of the in vivo microenvironment, more advanced 3D cancer models have
been developed using biological gels as a substrate for spheroid growth. Pio-
neering work has been based on the use of biomaterials from natural origins,
principally Matrigel and collagen [45]. Matrigel is a basement membrane
extract derived from the Engelbreth-Holm-Swarm mouse sarcoma that con-
tains a diverse array of components, including collagen type IV, laminin, and
other ECM molecules, as well as various soluble signals, such as cytokines
and growth factors [43]. Spheroids developed from culturing cell lines within
collagen gel culture have been used in chemotherapeutic testing and show
increased drug resistance compared to the same cell lines grown in mono-
layer cultures [43]. Alginate is other natural polymer gels used for cancer
cell cultures, derived from brown seaweed. It has been used as a scaffold
for encapsulation of various types of cells. The main advantage associated
with alginate is that gelation can be accomplished at room temperature af-
ter adding the cells to the polymer. Hydrogels also provide the possibility of
conjugation with defined adhesion ligands or delivery of specific biomolecules
(growth factors, pro-angiogenic factors, amongst others) [46]. When encap-
sulated within a 3D gel, cancer cells will often aggregate into 3D spherical
structures. Experiments have revealed that phenotypically differences be-
tween malignant and normal epithelial cells can be exclusively observed in
3D cultures, in which malignant cells lose tissue polarity and organization,
phenomena not commonly detected in 2D. Therefore, the remarkable plastic-
ity of cancer cells under different experimental conditions can be easily repro-
duced by using 3D cultures, which enable reestablishment in vitro crosstalk
among neighboring cells and their surrounding stroma [45].
Microscaffold based approach
Besides using self-assembled multicellular spheroids as in vitro models for the
testing of novel drugs, carrier or delivery systems, there are also a comparable
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number of studies that make use of scaffolds for in vitro tumor modeling [42].
Scaffold-based systems provide a platform where cells are grown in a semi-
solid matrix that allows the study the influences of mainly external physical
factors on microspheroid growth and signaling [7]. 3D scaffolds mimic ECM
of connective tissues and provide architectural support for tissue engineering
and regeneration with select cell types [23]. To attain an accurate recre-
ation of in vivo TME, the scaffold material of choice to replicate ECM would
need to satisfy two key requirements: molecular composition and stiffness.
In general, scaffolds can be categorized into two groups: natural and syn-
thetic scaffolds [42]. Based on the nature of the scaffolding materials, they
are either biodegradable or non-biodegradable and biocompatible or non-
biocompatible. Biomaterials, either natural or synthetic, that are biodegrad-
able and biocompatible are highly demanded in tissue engineering and 3D
tumor models [23]. Natural scaffolds are mainly composed of a wide range of
hydrogels. Generally, the hydrogels are mechanically weak but they provide
a biomimetic environment that supports cell proliferation and differentiation.
Most of the hydrogels used are made up of naturally occurring materials or
proteins found in the ECM. One of the many examples is collagen type I.
A recent study have demonstrated the ability of collagen type I hydrogels
in supporting the development of 3D in vitro biomimetic engineered tumors.
The fidelity of this tumor model in mimicking parts of pre-vascularized stages
of the native solid tumor progression, such as the development of necrotic
regions and intracellular hypoxia with increasing tumor size was validated by
the expression and upregulation of hypoxia-inducible factor (HIF)-1α [42].
Besides collagen gels, HA hydrogels represent another type of natural scaffold
that many studies have explored for use in engineered 3D tumor models [42].
These matrices have produced important conceptual advances, since they
have achieved the over-expression of tumor genes (EMT markers, MMPs,
pro-angiogenic factors) and the acquisition of drug resistance compared to
2D cultures, mimicking the in vivo cellular response. On the other hand, the
in vivo stiffness values can be easily recreated by increasing concentration or
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cross-linking density of these biomaterials. The composition and stiffness of
the tissue can be a critical variable depending on the animal origin and the
isolation and purification procedures, compromising assay reproducibility. To
overcome all these drawbacks, a further step in cancer biology involved the
development of synthetic biomaterials. With advancements in the biomate-
rial field, scaffolds can be readily fabricated from various synthetic polymers,
which are biodegradable and easily adapted into the appropriate shapes for
use in different applications. These synthetic polymers, with better mechan-
ical strength as compared to their natural counterparts, have been actively
employed for use in the construction of 3D tumor models [42]. Polyethy-
lene glycol (PEG), poly(lactide-co-glycolide) (PLG), poly(lactic-co-glycolic
acid) (PLGA) and polylactic acid (PLA) [45] materials are among the wide
range of synthetic scaffolds utilized for this purpose (Fig. 1.5). Most of these
scaffold-based systems allow controlling spheroid size by adjusting pore-size
and density. Among the studies on 3D cancer cell growth within synthetic
scaffold, Mooney and colleagues (2007), employed a porous PLG scaffold to
investigate the angiogenic properties of cancer cells in a 3D environment.
They found that comparisons of angiogenic factor secretion and drug re-
sponsiveness of tumors engineered in the PLG scaffold or in standard 3D
Matrigel culture indicate that, in some situations, tumors grown in the PLG
scaffolds may be more appropriate models to study certain aspects of cancer
progression [32].
Selection of the ideal biomaterial scaffold for a given cell type is problem-
atic and has been accomplished to date mostly by trial and error. Even if
the right biomaterial is available, achieving a high enough cell density and
the homogeneous cell distribution necessary to construct a viable tissue is ex-
tremely time consuming. Furthermore, preshaping the scaffold may present
further difficulties. To overcome these limitations, recent efforts have been
concentrated on scaffold-less tissue engineering and bottom-up approaches
aimed at generating a larger tissue construct by the assembly of smaller
building blocks, which mimics the in vivo tissue structure of repeating func-
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Figure 1.5: Scaffold based-models either with a natural isolated matrix (Ma-
trigel, left) or synthetic matrix (bottom) controlling matrix stiffness and
influencing physical factors [7].
tional units. An example of a bottom-up approach was used by Du et al.
(2008), to direct the assembly of cell-laden microgels to generate 3D tissue
with tunable microarchitecture and complexity [49]. McGuigan and Sefton
(2006), proposed another interesting use of modular components for generat-
ing tissue. In their approach, rod-shaped collagen microgels that were seeded
with HepG2 hepatocytes on the inside and endothelial cells on the surface
were ”packed” together within a bioreactor and perfused with medium [50].
Netti and co-workers (2010), produced a new microtissue precursor assembly
strategy (µTP) to produce pieces of viable 3D tissue-equivalent to resemble
and capture the major features of native tissue. In particular, µTP were
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obtained by means of dynamic cell seeding of bovine fibroblasts on porous
gelatin microcarriers using a spinner flask bioreactor [51] (Fig. 1.6). They
suggested that the porous structure of microcarriers created a suitable envi-
ronment for the development of fibroblasts, as the cells within the interior
will experience lower shear forces than those encountered with non-porous
carriers. Furthermore, under optimal culture conditions cells were able to
adhere, proliferate and in particular synthesize ECM components to form a
thin layer of tissue around the microbeads [44].
Figure 1.6: CAF-spheroid vs CAF-µTP. Multiphoton image of CAF-spheroid
(a) and CAF-µTP (b). Light grey indicates SHG signal. Scale bar 100 µm
[44].
Ultimately, 3D cultures, both spheroids and scaffold based-models, can
contribute to the reduction in animal testing and allow for economical savings
as well as become a powerful model to optimize drug candidates for enhanced
tissue distribution and efficacy [45].
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1.3 Microfluidics in tumor biology
1.3.1 General principles of microfluidics
Microfluidics - the science of manipulating small amounts (10−9 to 10−18 L)
of fluids in microfabricated hollow channels - is a microsystem technology
that has been used to generate and precisely tune dynamic fluid flows and
spatio-temporal gradients, as well as deliver nutrients and other chemical
cues to cells in a controlled manner [52]. Owing to their small size, fluid
flow in microfluidic systems is entirely laminar (no turbulence) and virtually
no mixing occurs between neighboring streams that flow beside each other
within the same hollow channel [52]. Microfluidics typically comprises sys-
tems involving fluids with geometries having characteristic length dimensions
on the order of tens to hundreds of microns. Microfluidics possesses a large
number of advantages, including being easy to fabricate, low reagent con-
sumption, parallel and rapid processing ability, and large-scale integration
[53].
Materials
Initial development of microfluidic devices focused on the application of con-
ventional silicon and glass micro-machining processes, but the emergence of
BioMEMS fabrication techniques such as replica molding has spawned the
development of microfluidic cell culture models in an array of materials plat-
forms including synthetic and natural materials as well as bioresorbable sys-
tems. Important considerations for the selection of substrate materials for
microfluidic cell culture models include optical transparency for cell imag-
ing, the desired degree of mechanical rigidity or flexibility, surface chemistry
and reactivity, and the ability to functionalize materials with chemical moi-
eties for modulation of cell-surface interactions. Synthetic polymers such
as PolyDiMethylSiloxane (PDMS) are the most common platforms for mi-
crofluidic systems and have been applied to cell culture models based on their
high oxygen permeability, optical transparency, and ease of fabrication [54].
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PDMS, a thermosetting polymer, is an attractive choice for the fabrication
of microdevices for the culture of cells and tissues. First, it has a high gas
permeability that ensures sufficient oxygen supply to cells in microchannels,
eliminating the need for separate oxygenators that are commonly required in
silicon, glass and plastic devices. Another advantage of PDMS is its optical
transparency from ultraviolet to the near infrared wavelengths [52]. While
the high permeability of PDMS to oxygen is often used to great advantage in
cell culture systems, its tendency to absorb, retain and release other chemicals
and some organic solvents in an unpredictable fashion has been a problem
for many applications [54]. Other materials with greater chemical stability
that have been used in microfluidics include cyclic olefin copolymers (COPs),
poly(methyl methacrylate) (PMMA), polycarbonate (PC), and polystyrene
(PS), the material traditionally used in static tissue culture dishes [54].
Fabrication
Methods for constructing microfluidic devices encompass a broad range of mi-
crofabrication techniques. The most commonly used approach is soft lithog-
raphy, in which a thermosetting polymer (often PDMS) is poured onto a
silicon mold featuring channel geometries, and is then cured and demolded.
Two pieces of the polymer are then laminated to generate a closed microchan-
nel. Master molds are typically fabricated using SU-8 photolithography, but
deep reactive ion etching, xenon difluoride, electroplating, and ultrasonic
milling have also been demonstrated to achieve a range of desired channel
geometries. In addition to solvent casting, other methods of fabricating de-
vices include hot embossing and injection molding COPs and polystyrene,
and traditional machining of materials such as polycarbonate [54].
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1.3.2 Microfluidics for mimicking tumor microenviron-
ment
Applications of microfluidic systems based on cell and tissue culture are now
emerging as platforms for high-throughput screening, drug discovery and
toxicity testing, and future directions include the development of organ as-
sist and organ replacement devices [55]. Today there are a vast number
of approaches using microfabrication to develop new cell culture platform
that recapitulate the characteristics of the in vivo environment [8]. Hence,
the combination of tissue engineering and microfabrication affords the de-
velopment of novel in vitro approaches to quantitatively assess constitutive
microenvironmental features that are frequently neglected by conventional
tissue culture methods or obscured by the complexity of in vivo models [11].
Microfluidic devices often accommodate fluid flow, an important physiolog-
ical condition not present within static culture dishes. Flow conditions in
microfluidic devices are useful for the application of fluid mechanical forces
to cells, the formation of gradients of oxygen, growth factors and other bio-
chemical signals, and maintenance of cell-cell communications [54]. Besides
the need to better understand the repercussions of fluid flow in the tumor
microenvironment, the inclusion of perfusion is also a potential strategy to
overcome the diffusional limitations associated with most 3D tumor models.
To achieve this goal of recapitulating tumor-associated fluid dynamics, tight
integration of the two most relevant engineering disciplines, microfluidics and
tissue engineering is necessary [43]. Recent advances in microfluidic technol-
ogy have made it possible to create a novel assays that allow precise control
of the cellular microenvironment [56]. Cells are embedded into a network
of channels and subjected to continuous flow [47]. A clear advantage is the
control of the liquid flow at in vivo relevant (capillary) dimensions, wchich
makes it possible to regulate nutrient and drug concentrations at the levels
of single cells or small clusters [8]. The laminar flow regime can easily be cre-
ated in a microchannel and are characterized by low turbulence and mixing
of parallel streams by diffusion only [8]. This condition presents the opportu-
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nity to mimic concentration gradients typical of the tumor niche, with better
recapitulation of drug transport and transient biological processes occurring
down to the single cell level [43]. Generally, the chemical gradients generated
by microfluidics include static and dynamic modes. The static modes often
rely on molecular diffusion in static liquid, so that continuous concentration
gradient can be formed. The formation of concentration gradients in dy-
namic modes, instead, is mainly based on the diffusion and the convection
of flowing liquid in laminar flow [53].
Figure 1.7: Diffusion and penetration of doxorubicin and therapeutic
Salmonella bacteria [57].
One of the most prominent manifestations of this research direction is
represented by the work of Jang et al., who developed a platform able to
evaluate up to 100 different drug combinations, in line with the emerging
importance of combinatorial drug therapy for chemoresistant patients. The
development of microfabrication techniques such as microcontact printing
and soft lithography further enhanced microfluidic capabilities, that is, bet-
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ter control over topology and surface chemistry, hence paving the way for
more sophisticated mechanistic investigations of tumor biology [43]. In order
to address the lack of interstitial fluid dynamics, recent studies tried to in-
tegrate spheroids into microfluidic platforms where spheroids were subjected
to interstitial fluid flow. In these models, spheroids were cultured within
polymeric matrices to mimic cell-matrix interactions in vivo, allowing for
the generation of spatial gradients of growth factors and pH. Walsh et al.
(2009), have created the pH gradient of the perfused spheroid culture on a
microfluidic platform, and visualized the doxorubicin diffusion through the
tumor spheroids (Fig. 1.7) [57].
Figure 1.8: Microfluidic cell culture system for investigating the effects of
interstitial flow on tumor cell migration [58].
Beyond being able to mimic the multicellular cross talk within the TME,
microfluidic culture systems have recently been shown to have utility in in-
vestigating the effect of interstitial flow on tumor cell migration. Polacheck
et al. (2011), developed a microfluidic platform to mimic stable pressure
gradients and fluid flow across the tumor interstitium. In this model, breast
cancer cells (MDA-MB-231) were seeded in type I collagen matrix and cul-
tured under the perfusion of interstitial flow created by pressure difference
across the matrix. By controlling the pressure of each media channel, the flow
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rate could be precisely controlled and its effects on cell migration behavior
were studied (Fig. 1.8) [58].
Recently several studies have been reported on microfluidic 3D environ-
ments for co-culturing different types of cells. Liu et al. (2010), have de-
veloped a microfluidic device for co-culturing tumor cells and CAF in an in
vivo-like 3D microenvironment and investigated the role of CAF in tumor
invasion in vitro. Communication between CAF and tumor cells could be
established via medium diffused in matrix (Fig. 1.9) [19].
Figure 1.9: Chip design and cell-loading steps. (a) Schematic representation
of the microfluidic chip for 3D cell co-colture. (b) A magnified illustration
of one co-colture unit. (c) Cross section of two co-colture units and medium
channel showing cell-loading steps [19].
Drifka et al. (2013), introduced an in vitro microfluidic model of pan-
creatic ductal adenocarcinoma (PDAC) microenvironment incorporating the
in vivo complexities of multicellularity, ECM components, and a rationally-
defined 3D microarchitecture (Fig. 1.10) [59].
Choi et al. (2015), described a biomimetic microengineering strategy
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Figure 1.10: Design and operation of the microfluidic device. (A) a device
after trilayer patterning (B) and a contarcted trilayer culture with media
(pink) added (C) three cell-ECM droplets are placed on the inlet ports and
simultaneously drawn into the central culture channel from the outlet. The
process of culture etablishment is depicted in cross-section (D-F) [59].
to reconstitute 3D structural organization and microenvironment of breast
tumors in human cell-based in vitro models. They developed a microsystem
that enabled co-culture of breast tumor spheroids with human mammary
ductal epithelial cells and mammary fibroblasts in a compartmentalized 3D
microfluidic device to replicate microarchitecture of DCIS (Fig. 1.11) [60].
1.4 Intravital microscopy to study tumor -
stroma interface
An approach to characterize TME components and observe its change follow-
ing pharmacological intervention with high spatial and temporal resolution
is with in vivo or intravital microscopy. Quantitative intravital microscopy
requires four components: first, a tissue preparation that allow visualization;
second, a molecular probe that can be detected by a microscope; third, a mi-
croscope and detection system; and fourth, computer algorithms and math-
ematical models that can be used to extract parameters of interest from
the optical information. The tissue preparations fall into two broad cate-
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Figure 1.11: (A) DCIS is embedded in a mammary duct consisting of the
mammary epithelium and a basement membrane surrounded by stromal tis-
sue that contains fibroblasts. (B) The microarchitecture comprises of the
upper and lower cell culture chambers separated by an ECM-derived mem-
brane that mimics a basement membrane in vivo [60].
gories: chronic-transparent windows and in situ preparations. Depending
on the experimental aim, an appropriate exogenous or endogenous molecular
probe is used [61]. Intravital microscopy includes a number of techniques
such as single-photon microscopy, multiphoton (MP) microscopy and opti-
cal frequency domain imaging. Among them, MP microscopy technique is
a powerful tool that has provided unprecedented mechanistic insights into
TME. It can be used to monitor and image the expression of specific protein
(for example Second Harmonic Generation SHG for fibrillar collagen) and
can be applied for the evaluation of different treatment strategies [10]. In-
travital imaging can be also used to understand tumor cell invasion dynamics
and how the native tumor environment can impact invasion and metastasis.
SHG is an optically nonlinear coherent process where the emitted light has
exactly half the wavelength of the two incident photons. The energy is thus
conserved and no absorption occurs. This makes SHG a powerful tool for de-
tecting and visualizing the 3D collagen network without labeling or staining.
Collagen fiber type I has the crystalline and non-centrosymmetric properties
required for generating the second-harmonic signal. Fibrillar collagen type
I consists of a triple helical macromeolecule that self-assembles into fibrils
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and fibers. The molecular organization, amount and distribution of fibrillar
collagen type I are important for the structural and mechanical properties
of tissue and play an important role in wound healing and in diseases such
as cancer [62]. The other forms of collagen (II, III, V) can be stained by
Picro-sirius red, an acidic dye, because they cannot be visualized by SHG
technique for their loss crystallinity.
Many groups have incorporated two-photon techniques to analyze colla-
gen SHG signals in an attempt to differentiate healthy and tumor tissue.
Morphological collagen changes, such as the shape of fibrillar collagen or its
orientation with regards to the border of primary tumor, have been investi-
gated in order to differentiate between healthy and malignant tumors [13]. In
particular, collagen changes at the tumor/stromal boundary can be imaged
and classified as markers of mammary carcinoma progression, called tumor-
associated collagen signatures (TACS). During tumor formation, mammary
tumors exhibit a localized increase in collagen deposition near tumor lesion
(termed TACS-1). It is unclear whether: 1) a pre-tumor dense region is
present that serves to stimulate tumor formation, 2) the dense region of col-
lagen is pulled into a grouped cluster through increased contraction of an
epithelial tumor mass or motile cells at the tumor boundary, or 3) fibrob-
last activation results in increased local collagen deposition [40]. As tumor
increases in size, a straightening of collagen fibers that are aligned parallel
to the tumor boundary is noted (TACS-2). Remodeling of the stroma pro-
gresses to the final stage, which is the reorientation of collagen such that
multiple collagen fibers are bundled and aligned perpendicular to the tumor
boundary and promoted tumor invasion (termed TACS-3). TACS-3 corre-
sponds to sites of focal invasion into the stroma. These specific definitions of
TACS are consistent with the general and well-known feature of desmoplasia,
a fibrous stromal deposition, surrounding tumors and help to identify breast
tumors in experimental animal models as well as human cancer and fresh
tumor biopsies [14] (Fig. 1.12).
Hompland et al. (2008), have studied the content and structure of colla-
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Figure 1.12: Tumor associated collagen signatures (TACS)[14].
gen by SHG signal in frozen sections from three tumor tissues (osteosarcoma,
breast carcinoma and melanoma) and compared them with corresponding
normal tissues (bone, breast, dermis/skin). They found a strikingly differ-
ence in collagen network between tumor and normal tissue, suggesting that
the collagen network in tumor tissue have lost most of their normal functions.
The osteosarcoma and breast carcinomas showed similar distributions. The
collagen cap in the periphery represented approximately 50 to 60% of the
area in this region, whereas only 0 to 9% of the section contained collagen
farther into the tumor. The cap was formed by long collagen fibers oriented
along the outer periphery and shorter fragments facing inward [62]. Burke et
al. (2013), utilized a quantitative analysis of the ratio of forward and back-
ward propagating SHG signal (F/B ratio) to monitor collagen throughout
ductal and lobular carcinoma development. In ductal carcinoma, there is
no significant alteration in fibrillar collagen microstructural properties com-
pared to healthy breast tissue, but there is an alteration in them as the
tumor progress from an in situ to an invasive carcinoma. This is consistent
with the fact that the majority of SHG collagen fibers in healthy tissue are
43
surrounding the ducts, so as the tumor cells exclusively fill in the ducts in
DCIS, the surrounding collagen microstructural properties remain relatively
unaffected. It is only when the tumor cells begin to invade the breast tissue
outside of the duct that they induce changes in microstructural properties
of the surrounding fibrillar collagen. ILC, instead, causes a change in the
fibrillar collagen microstructural properties in breast tissue, as indicated by
a decrease in the F/B ratio relative to healthy tissue (Fig. 1.13) [13].
Figure 1.13: Sample images of five types of tissue analyzed: healthy tissue,
DCIS, LCIS, IDC and ILC. The left column shows H-E staining, the middle
columns show backward- and forward- scattered SHG, and the right column
the F/B ratio image[13].
The morphology of collagen fibers revealed by SHG can also be quan-
titatively described by Texture analysis. Texture analysis approaches can
be categorized into statistical, structural, model-based and transform-based
methods. As the most frequently cited statistical method, the gray level co-
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occurrence matrix (GLCM) has been applied to a variety of field for decades,
including texture analysis to quantitatively analyze the collagen fibers. Gen-
erally, GLCM features along one or two of the four specific directions of 0
deg, 45 deg, 90 deg and 135 deg can be extracted to quantitatively analyze
SHG images. Since the orientation is an important characteristic of collagen
fibers with a filamentous structure, the GLCM features calculated along the
dominant orientation of collagen fibers are different form those calculated
along the other directions. By combining the dominant orientation of col-
lagen fibers into GLCM analysis, the GLCM curves calculated may provide
more information for detailed morphological characterization of the collagen
fibers, thus leading to further sights into various physiological and patholog-
ical processes, such as the structural modification of the extracellular matrix
during the migration and invasion of tumor cells [63].
Zhuo et al. (2010), established a quantitative link between collagen alter-
ation and epithelial tumor progression using SHG microscopy. They found
that SHG microscopy could provide quantitative features to effectively eval-
uate epithelial tumor progression and to determine the margin of tumor
regions. To relate the collagen fibril structure, they used the correlation fea-
ture that is a measure of intensity correlation as a function of pixel distance.
As seen in (Fig. 1.14), normal correlation fell off sharply with pixel distance
indicating distinct, linear fibrils, whereas the precancerous and cancerous fib-
rils correlation remained elevated as pixel distance increased, implying less
defined fibrillar structure [64].
Adur and co-workers (2014), showed similar results working with ovarian
tumors. Using this methodology they found that it is possible to discriminate
between cancerous and healthy tissue with clear cut distinctions between
normal, benign, borderline and malignant tumors of serous and mucinous
ovarian tumor types (Fig. 1.15 ) [65], [66].
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Figure 1.14: Correlation value as a function of pixel distance from normal,
precancerous and cancerous epithelial tissues [64].
Figure 1.15: Correlation values in serous ovarian tumors versus distance [66].
1.5 Nanotechnology in cancer treatment and
diagnosis
Conventional chemotherapeutic agents are distributed non-specifically in the
body affecting both normal and tumoral cells. Given the potency of modern
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pharmacological agents, tissue selectivity is a major issue. The ultimate goal
of cancer therapeutics is to increase the survival time and the quality of life
of the patient by reducing the systemic toxicity of chemotherapy. In this con-
text, the tumor targeting of nanomedicine based therapeutics has emerged as
one approach to overcome the lack of specificity of conventional chemothera-
peutic agents [67]. The field of nanomedicine has recently attracted tremen-
dous attention, particularly for applications in cancer drug delivery. Owing
to the advancements in material science and new manufacturing methods,
nanoparticle (NPs) drug delivery platforms can now be fabricated to an al-
most unlimited number of configurations with respect to size, shape, and
payload, allowing for versatile applications for the detection, prevention and
treatment in oncology [68]. Nanoparticles can be designed to target tumor
cells, vasculature or different types of cells such as immune cells to achieve
anti-tumor responses such as anti-angiogenic therapy, immunotherapy or cy-
totoxic therapy. In a systematic point of view of an in vivo system, it is
necessary to understand how nanoparticles can target tumors, how they dif-
fuse through the TME and how they interact with individual cells to perform
their therapeutic function (Fig. 1.16) [69].
Figure 1.16: The concept of biomimetic tissue-engineered for evaluation of
nano-based therapy. Colors: glod/blue: nanoparticle; green: cancer cells;
red/pink: blood vessel, endothelial cells; blue: immune cells [69].
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Several nanostructured particles are being developed for therapeutic ap-
plications with different chemical nature such as metallic, polymeric or ce-
ramic and different morphologies such as nanospheres, nanorods, nanotubes,
nanowires, nanocubes and nanocages. Their surface may be functionalized
with biomolecules such as antibodies, peptides, oligonucleotides or polymers
like PEG [69]. Nanotherapeutics such as liposomes, polymeric micelles and
inorganic NPs possess a distinct functional advantage or conventional small
molecule chemotherapy regimens by overcoming severe systemic toxicities
that limit the clinical application of most chemotherapy drugs. Furthermore,
nanoparticle drug delivery platforms permit significantly prolonged circula-
tion when compared to small molecule drugs alone [68]. Recent advances
in nanotechnology have led to the development of particles with control-
lable size and surface charge and with the potential to be used for cancer
detection and treatment [70]. Examples of applications include both the pre-
clinically investigated nanoformulation (liposomes, polymeric micelles) and
FDA approved NPs of liposomal doxorubicin (Doxil) and albumin-bound pa-
clitaxel (Abraxane) [68]. To achieve effective targeted drug delivery, various
strategies have been proposed to exploit these pathophysiological character-
istics of the TME. Currently NPs are designed based on so-called ”passive”
and ”active” targeting strategies, which rely on increased extravasation and
ligand-receptor interactions, respectively. The passive targeting is based on
the fenestration and prolonged circulation by PEGylation. The term ”active
targeting” is used to describe a strategy bind to the target tumor cells or
endothelium. Active targeting becomes effective only after the NPs reach
the vicinity of the target tumors [9].
Now there is an emerging need for better understanding of how these
particles diffuse in the ECM and for prediction of the particle properties
that optimize their delivery to cancer cells [70].
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1.5.1 Drug distribution in solid tumors
The complex TME poses multiple barriers that inhibit transport and action
of drugs. First, the TME serves as a biophysical barrier that impedes effective
transport of drugs to target cancer cells or associated stromal cells. After
being administered into a patient’s bloodstream, drugs are thought to be
subjected to complex and multi-faceted transport processes prior to reaching
the cancer cells [9]. In general, the intratumoral delivery of macromolecules
and NPs require several steps in transport, including:
1. vascular transport;
2. transvascular transport;
3. interstitial transport;
4. cellular binding, internalization and metabolism [68] (Fig. 1.17).
1.17
Within the tumor stroma, convective and diffusive forces are intrinsic me-
diators of the biochemical landscape that sustains neoplastic development.
The predominant conduits of mass transport, microvascular networks define
the spatial distribution of oxygen, nutrients, endocrine signals, and thera-
peutic drugs. Moreover, as a consequence of diffusion-limited nutrient and
waste transport, the absence of a functional vasculature regulates the de-
velopment of hypoxia and acidosis during tumor initiation and at interior
regions of advanced cancers [11]. Compared to healthy vasculature, tumor-
associated blood vessels exhibit increased leakiness, tortuosity, instability via
absence of mural cells and subsequent aberrant fluid mechanical forces. No-
tably, by contributing to elevated fluid pressure in the tumor, dysfunctional
vasculature compromises drug delivery and modulates interstitial flow at the
tumor margins [11]. To better understand the biophysical underpinnings
of these transport barriers, Jain and his colleagues (2010), have developed
several mathematical models to simulate the intratumoral behaviors of NP
[71]. For the modeling of vessel and trans-vasculature transport, the tumor
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Figure 1.17: Scheme of NP intratumoral transport [68].
vasculature was represented by a two-dimensional percolation network with
one inlet and one outlet that resembles the vascular structure and function
of tumors. Vessel transport is mainly dominated by convection (flow rate
governed by pressure gradient) and is quantified based on the perfusion rate
of blood flow (Q). Poiseuille’s law was used to simulate vessel transport, sug-
gesting that blood flow is proportional to the vascular pressure gradient and
blood viscosity [68]. The transvascular flow was set proportional to hydraulic
conductivity of the vessel wall, the surface area of the vessel and also the in-
fluence of IFP. Interstitial transport, mainly indicating the diffusion of NP
through the ECM toward tumor cell targets, is another significant step in
determining NP penetration [68]. This phenomena is dependent on convec-
tion and diffusion [41]. The sum of convective JC and diffusive JD fluxes is
given by the following equation (Darcy’s theory):
Js = JD + JC = −D∇C + vffC (1.1)
50
where D is the effective diffusion coefficient, C is the solute concentration,
f is the retardation coefficient, and vf is the interstitial fluid velocity, deter-
mined by the solution to the Brinkman equation for flow through porous
media:
µ∇2vf − vf
K
−∇ρ = 0 (1.2)
where µ is the fluid viscosity, K is the hydraulic conductivity and ρ is the
hydrostatic pressure difference between the vascular and lymphatic vessels
[41]. After extravasation, the drug is transported through the tumor inter-
stitial space against elevated tumor IFP and abnormal ECM structure. The
IFP of a solid tumor stays at an elevated level and sharply decreases at the
periphery of the tumor [9].
In general, diffusion of macromolecules or NP in the ECM was mod-
eled in vitro using matrigel or collagen confined diffusion chamber models.
Diffusion coefficients were determined using these in vitro ECM models by
non-linear fits of intensity gradients to a diffusion model (Fickian model)
or can be quantified in vivo using either single-photon Fluorescence Recov-
ery After Photobleaching (FRAP) or two-photon Fluorescence Correlation
Spectroscopy (FCS) [68]. Convection depends on gradients of pressure (both
hydrostatic and osmotic) between vascular and interstitial space; vessel per-
meability and the surface area of exchange. In the case of tumor, the com-
bination of leaky vasculature and dense ECM increases IFP and inhibits
convection-mediated transport. Consequently, drug-delivery within tumor
stroma primarily depends on diffusion. Hypoxia can also induce the activa-
tion of cell survival or pro-angiogenic genes, leading to certain populations of
cells that become drug-resistant. Additionally, drugs that rely on an oxygen-
based free-radical mechanism cannot function on cells in a hypoxic (oxygen
low) environment. pH is also low in the extracellular space of hypoxic tumors,
causing weakly basic drugs to become protonated, hindering their ability to
cross the cell membrane. Composition and organization of the tumor ECM
can also determine whether drugs can penetrate into the tumor. Exces-
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sive ECM deposition due to fibrotic remodeling physically hinders diffusion
of large anti-tumor molecules through the interstitium [41]. However, dense
cellular and matrix components represent diffusion barriers that hinder trans-
port through the interstitium in conjunction with elevated IFP (Fig. 1.18).
Specific parameters that regulate diffusion efficiency through the stroma in-
clude: 1) diffusion distance, 2) available volume fraction of pores (accessible
space where molecules can pass through), 3) tortuosity of pathway, 4) hy-
drodynamic resistance, and 5) ECM affinity of the molecule of interest. All
of these parameters are affected by tumor stroma remodeling. For example,
desmoplasia-mediated enhancement of ECM density and structural changes
decrease the available volume fraction of pores and increase the tortuosity of
the void space, both of which reduce the rate of diffusion through the stroma
[41].
Figure 1.18: ECM-conferred barriers to treatment [25].
Furthermore, properties of drugs (size, charge and configuration) influ-
ence the diffusion of drug [41]. Drugs or molecular probes perform Brownian
random walks through the spaces between network structures and are influ-
enced by components of the matrix in three distinct ways: 1) they collide
with matrix fibers (steric interactions); 2) as they diffuse near fibers, re-
stricted thermal motion of water molecules due to proximity to the fibers
slows their diffusion (hydrodynamic interactions) and 3) for charged parti-
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cles, electrostatic interactions with charged components of the ECM con-
tribute an additional force [70]. Stylianopoulos et al. (2010), presented a
mathematical framework to study the effect of charge on the diffusive trans-
port of macromolecules and NP in the ECM of biological tissues. The TME
consists of fibers whose diameter ranges from a few nanometers (HA, colla-
gen oligomers) up to a few micrometers (collagen fibers) and their charge can
be either positive (collagen) or negative (HA). Therefore, neutral particles
should diffuse faster than cationic. Since cationic particles are preferred be-
cause they target tumor vessels, the optimal NP for delivery to tumor tissue
should be initially cationic to selectively target tumor vessels, but change
charge to neutral after entering the ECM [70]. Diffusion of drugs is also
limited by binding in tissue or by their rapid metabolism once they have ex-
travasated. An important determinant of drug distribution within tissue is
the half-life of the drug in the circulation; drugs having a long half-life have a
better opportunity to achieve equilibrium within TME [72]. For example, the
poor penetration through tissue of a most common used drug, doxorubicin,
is due to binding to DNA and sequestration in acidic endosomes of cells
that are proximal to the vasculature [73]. The specific structure of ECM
components also modulates diffusion fluxes of therapeutic molecules. Analy-
sis of collagen fiber orientation via SHG revealed that increased malignancy
is associated with collagen fiber re-orientation. While collagen in initiating
tumors is characterized by isotropic orientation, progression leads to tan-
gential and ultimately radial alignment in expanded and invading tumors,
respectively. These changes in ECM fiber network orientation can promote
diffusion anisotropy without affecting the overall diffusion coefficient of the
drug. For example, fibers tangentially aligned to the tumor boundary could
redirect drug diffusion away from the tumor and therefore, impair therapy ef-
ficacy during the initial stage of tumorigenesis. Theoretically, radially aligned
fibers should mediate the opposite effect; however at this stage tumor cells
may have developed resistance phenomena rendering them unresponsive to
therapy. The opportunity for enhancing drug transport by modifying tumor
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matrix was demonstrated in a mouse model of pancreatic cancer, where gem-
citabine delivery was improved through depletion of desmoplastic stroma by
inhibition of Hedgehog signaling [74]. A recent report by Lu et al. (2015), in-
dicated that cellular density is another factor affecting interstitial transport.
Densely packed tumor cells induce a solid stress and reduce the interstitial
space for NP transport [68]. Many anticancer drugs exert their action by
binding to macromolecules. Earlier studies using tumor cell spheroids have
shown that penetration of protein-binding drugs such as doxorubicin and
paclitaxel is limited to the periphery [75]. High binding affinities between
drugs and the target site are generally seen as an advantage by increasing
the internalization of drug. However, the use of targeted drug with high
binding affinity may elicit a binding site barrier. This regards a phenomenon
where drug binding to target cells paradoxically reduces diffusion deep into
tumors [68]. Once the drugs are transported through the tumor interstitial
space, they should act on tumor cells, but their efficacy may also be limited
due to complete or partial drug resistance. Multidrug resistance (MDR) is
thought to be caused by a group of membrane proteins that extrude cytotoxic
molecules, thus maintaining the intracellular drug concentration below effec-
tive levels. These proteins belong to the ATP binding cassette superfamily
of membrane transporters, most of which use the energy of ATP hydrolysis
for the eﬄux of drugs (active transport). This family includes the well-
characterized P-glycoprotein (Pgp) encoded by MDR-1 gene, the multidrug
resistance protein (MRP) and the mitoxantrone resistance protein (MXR),
also known as the breast cancer resistance protein (BCRP). In addition to
the over-expression of these transporter proteins, cellular drug resistance also
appears to be mediated by the binding of tumor cells to the ECM [9].
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Chapter 2
Metabolic activity, mechanical
properties and ECM
composition evolution of
spheroid and microtissue model
2.1 Introduction
The progression of cancer is no longer being considered as an independent
event which only relates to the genetic mutation and uncontrollable growth of
cancer cells [76]. There is growing evidence that biological behavior of cancer
cells, such as proliferation, invasion and metastasis, is profoundly influenced
by the presence of host stromal cells [2]. Among stromal cells, fibroblasts
are the major components that surround cancer cells [2]. It is well known
that fibroblasts play an important role in the carcinogenic process [77]. In
addition to provide a mechanical support, fibroblasts are also involved in the
deposition of extracellular matrix (ECM), in controlling proliferation and
invasion of cancer cells as well as in enhancing of therapy resistance [78],
[2]. On the other side, fibroblasts undergo changes in the upregulation of a
variety of molecules such as growth factors, matrix degrading enzymes, an-
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giogenic factors and cytokines in stromal compartment [79]. This dynamic
interplay between tumor and fibroblasts cells is probably due to a substan-
tial phenotypic transformation from normal to activated cancer fibroblasts
(CAF) [80]. Furthermore, during tumorigenesis, the continuous remodeling
of ECM by CAF contribute in modifying mechanical properties of stromal
fibroblasts [81]. As the same time, tissue mechanosignaling activates protu-
morigenic signal pathways that simultaneously promote carcinogenesis and
metabolic alterations [81]. CAF play an active role in supporting metabolic
reprogramming of tumor cells by recycling products of anaerobic metabolism
in order to sustain cell survival [82]. For these reasons, the complex mech-
anisms of tumor progression cannot be investigated without the presence of
tumor stroma [83]. It has been widely demonstrated that the complexity
and heterogeneity of the tumor microenvironment cannot be replicated in
two-dimensional (2D) models due to unreliable clinical response [84]. On the
contrary, three-dimensional (3D) culturing methods provide a valid alterna-
tive to better recapitulate in vitro the in vivo structure of tumor tissue [85].
Whereas the morphological properties and cell-matrix interactions of tumor
and stromal cells are flattened in 2D systems, these aspects can be reliably
distinguished when cells are cultured as aggregates (spheroids), grown on
3D scaffold materials, or embedded in gels [86]. Among them, spheroids are
the most used models in cancer research. Despite their success, they have
experimental limitations since only few works incorporate stromal cells in
spheroid models [87]. As result of progresses in tissue engineering, some re-
search groups are focused on the realization of scaffold materials to create
a more reliable 3D cancer models [44]. Microtissue precursors (µTP) are an
example of scaffold-based tissue model [51]. In such models, cells are in-
duced to grow onto microcarriers surface and within their pores are able to
synthesize endogenous ECM under controlled culture conditions [6].
In this work we focalize only on the stromal component of tumor mi-
croenvironment consisting of fibroblasts. In particular normal fibroblasts
and CAF are seeded on porous gelatin microcarriers in a dynamic culture
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system according to previous works [6], [51]. In parallel the same typology
of cells were grown in spheroid configuration. The intention is to monitor
the dynamic evolution of the metabolic activity, mechanical properties and
ECM compositions in both investigated models (spheroids and µTP). Inter-
estingly, only in µTP configuration phenotypic differences between normal
and activated fibroblasts were found.
2.2 Materials and Methods
2.2.1 Cell type
Human normal mammary fibroblasts (NF) and cancer associated fibroblast
(CAF), kindly donated by Kojima’s group, were sub-cultured onto 150 mm
Petri dishes in Dulbecco’s Modified Eagle Medium (DMEM) with high glu-
cose, containing 10% fetal bovine serum, 100 µg/ml L-glutamine, 100 U/ml
penicillin/streptomycin. Cells were maintained at 37 ◦C in humidified atmo-
sphere containing 5% CO2.
2.2.2 Microscaffold production
Gelatin porous microbeads (GPMs) have been prepared according to a mod-
ified double emulsion protocol (O/W/O) [88]. GPMs have been stabilized by
crosslink reaction with GPMs glyceraldehydes (GAL), in order to make them
stable in aqueous environment at 37 ◦C, as previously described [6]. GAL at
5% w/w of the microbeads has been used to perform all the experiments.
2.2.3 Homotypic cell culture
All cell cultures on microscaffolds were performed in spinner flask (Integra).
For homotypic culture (NF, and CAF) 50 mg of GPMs were loaded together
with 7.5*105 cells (30 cell/GMP ratio). To promote cell seeding on GMPs an
intermittent stirring regime (30 min at 0 rpm, 5 min at 30 rpm) for 6 h has
been performed. To monitor the seeding efficiency during the post-inoculum
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time, the disappearance of free cells from the inoculated spinner cultures was
calculated as [(C0 − Ct) ∗ 100]/C0 where C0 is the concentration of the cells
at the inoculum time and Ct the concentration of the cells in the culture
medium. Then, dynamic cultures were kept under continuous stirring at 30
rpm for up to 12 days. Medium was changed on the first day and every
3 days until the end of the experiments. From the second day of dynamic
culture, 50 µg/ml of ascorbic acid were added. Microtissues (µTP) samples
were taken for further investigations at days 1, 4, 8 and 12 for homotypic
cultures and fixed.
2.2.4 Spheroid formation
Cells were trypsin-treated and counted. Subsequently, they were seeded onto
round bottom non-tissue culture treated 96 well-plates (Falcon, BD NJ, USA)
at a concentration of 2500 cells/well in DMEM High Glucose, 10% FCS
supplemented with 20% methyl cellulose stock solution. For preparation
of methylcellulose stock solution we autoclaved 3 grams of methylcellulose
powder (M0512, Sigma-Aldrich) in a 250 ml bottle containing a magnetic
stirrer. The autoclaved methylcellulose was dissolved in preheated 125 ml
basal medium (60 ◦C) for 20 min (using the magnetic stirrer). Thereafter,
125 ml medium (RT) containing double amount of FCS (20%) was added to
a final volume of 250 ml and the whole solution mixed overnight at 4 ◦C. The
final stock solution was aliquoted and cleared by centrifugation (5000 g, 2
h, RT). Only the clear highly viscous supernatant was used for the spheroid
assay (about 90 − 95% of the stock solution). For spheroid generation we
used 0.24% methylcellulose. Spheroids were grown under standard culture
conditions (5% CO2, at 37
◦C) and harvested at different time points for
further investigations.
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2.2.5 Tissue micromodules/entities morphology
A 200 µl aliquot of NF and CAF µTP homotypic culture at time 4, 8 and 12
day on a 35 mm Petri dish were observed with a light microscope (Olympus,
BX53). Ten images were taken at the same magnification for each sample
at every time-point. 1 ml of µTP and spheroids suspension was fixed in a
solution of 10% neutral buffered formalin for 1 h at RT, dehydrated in an
incremental series of ethanol (75%, 85%, 95% and 100% twice, each step 30
min at RT) treated with xylene and paraffin embedded. Successively, the
samples were sectioned at a thickness of 7 µm. Masson’s trichrome (Sigma
Aldrich) staining was performed according to standard protocols. At last,
the sections were mounted with Histomount Mounting Solution (Bioptica)
on coverslips and the morphological features of µTP and spheroids were
observed with a light microscope (Olympus, BX53).
2.2.6 Cell proliferation
At the day 1, 4, 8 and 12 of culture, 1 ml aliquots were collected for cell growth
monitoring on the GPM. Briefly, 200 µl of the same aliquots was transferred
to a cell culture dish (w/2 mm grid Nunc) for microcarrier counting, after
which the microcarrier suspension was placed in a new 2 ml tube and washed
twice with PBS. To detach cells from microcarriers, µTP were digested by
collagenase A (Roche Life sciences, Italy) 60 min at 37 ◦C, centrifuged 5 min
at 2000 rpm, and incubated 5 min in Trypsin (Lonza, Italy). The detached
cells were then counted using a hemocytometer. In the same way, a 96-well
plate (Falcon, BD NJ, USA) of NF and CAF spheroids was trypsin-digested
for each time point in order to obtain the cell number for spheroids at each
time-point.
2.2.7 Oxygen consumption kinetics measurement
In order to evaluate the oxygen consumption kinetics, a known amount of
NF and CAF µTP, and NF and CAF spheroids were spilled from the spin-
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ner flask and round bottom 96 well-plates respectively at day 4, 8 and 12
days of culture and placed in three different vials of frosted glass. The vials
were filled with fresh culture medium, placed in an incubator and kept at
37 ◦C, under gentle agitation. The vials were, then, sealed in order to avoid
oxygen exchange with the surrounding environment. The decrease of oxy-
gen concentration in the medium, due to cell metabolism, was measured by
means of an optical detector (OXY-4 PreSens) placed in the vials. The mea-
surements were performed until the oxygen was completely consumed. The
oxygen consumption took place in 4-5 h depending upon the number of µTP
and spheroids used. The partial pressure was converted in oxygen concentra-
tion (mM) by means of Henry’s law. As a control, the same measurements
were performed in three vials containing only medium at the same condi-
tions. In parallel, a known amount of µTP and spheroids were enzymatically
treated and the cell number was counted in order to obtain the cell number
per µTP and spheroid respectively. By performing centred time derivative
of the oxygen concentration curve, it was possible to obtain the plot of the
consumption rate versus the oxygen concentration for each construct. This
curve was fitted by the following Michelis-Menten Eq. 3.1:
R =
ρVmaxC
Km + C
(2.1)
where ρ is the cell number divided by the volume of the vial, Vmax is the
maximum rate of consumption, Km is the oxygen concentration at which the
rate of oxygen consumption is half of the Vmax value and C is the oxygen
concentration. The fitting parameters were Vmax and Km.
2.2.8 Evaluation of pH tissue microenvironment
The pH value of the culture medium was read out for both NF µTP and
spheroids and CAF µTP and spheroids respectively. For each tissue con-
struct, the culture mediums were collected from spinner flask and round
bottom 96 well-plates and the corresponding pH were read by using a pH-
meter (mettler-toledo) respectively at day 4, 8 and 12 days of culture. A
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simple of 5 ml of NF and CAF µTP were spilled by spinner flask after cell
seeding and placed in a low attachment petri dish (corning) until the 4th
day for first acquisition point. In parallel, the mediums of 25 wells of NF
and CAF spheroids were collected for pH measure. The µTP and spheroids
were enzymatically treated and the cell numbers were counted in order to
obtain the total cell number for each construct. The pH, closely depend
upon the cell number and the culture medium volume, whereby the value
was converted in [H+] expressed in mol/L following the Eq. 3.2:
[H+] = 10−pH (2.2)
In order to obtain the contribution of H+ ions per cell (′H+), [H+] was
multiplied by the total volume of culture medium and divided by the total
cell number for each tissue model following the Eq. 3.7
′H+ =
[H+]V
N
(2.3)
where V is the total volume of culture medium and N is the total cell
number in the spinnes flask. This operation was repeated at 8 and 12 days,
and each measure was repeated in three independent experiments.
2.2.9 Multi-particle tracking
A custom-made multiple particles tracking microrheology (MPT) appara-
tus was used to probe the local mechanics of the cytoplasm by monitoring
and tracking the motion of particles embedded in the samples. Fluorescent
polystyrene particles (100 nm Polyscience) were shot in the cells using a bal-
listic gun (Bio-Rad, Hercules, CA). Helium gas at 2200 psi was used to force
a macrocarrier disk coated with particles to crash into a stopping screen. The
force of collision was transferred to the particles, causing their dissociation
from the macrocarrier and the bombardment of the cells. Then, the sam-
ples were placed in a microscope stage-incubator at a controlled temperature
and CO2 (37
◦C and 5%, respectively). Movies of embedded particles were
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recorded via a gated intensified highspeed camera (Lambert Instruments, Ro-
den, The Netherlands) mounted on an inverted epifluorescence microscope
(Olympus IX70, Olympus, Melville, NY) at 100 X magnification. The dis-
placements of particle centroids were monitored by a time-lapse acquisition
of 6 s at a rate of 50 frames per second. Movies of particles were analyzed
by a self-developed algorithm in Matlab (Matlab 6). It detects each position
in every frame by intensity measurements and links this point detection into
trajectories, based on the principle that the closest positions in successive
frames belong to the same particle (proximity principle). Once the trajecto-
ries had been obtained, mean square displacements (MSD) described by the
Eq. 3.8:
MSD =< ∆r2 >=< [x(t− τ)− x(t)]2 + [y(t− τ)− y(t)]2 > (2.4)
were obtained. In the Equation 3.8 the symbol ” <> ” means time aver-
age, is the time scale and t the elapsed time. The MSD provides information
about the mechanical properties of cytoplasmatic environments. Indeed, it
was demonstrated that the MSD amplitude is inversely related to the rheo-
logical properties of living cells [89] here we evaluated MSD after 12 days of
culture to gather information about the mechanical organization of the cells
in each configuration.
2.2.10 Multiphoton imaging
Two-photon excited fluorescence was used to induce Second Harmonic Gen-
eration (SHG) and obtain high-resolution images of unstained collagen struc-
tures in µTP’ ECM. Homotypic µTP samples were used for SHG analysis.
Hence, all the samples were imaged by two-photon excited fluorescence at λex
= 840 nm to induce SHG of unstained neo-synthesized collagen structures
by collecting the emission wavelength in the range λem = 420 ± 5 nm.
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2.2.11 Collagen amount quantification
SHG images from NF and CAF µTP and NF and CAF spheroids were an-
alyzed by using ImageJ software. In order to quantify the collagen fraction
in the endogenous ECM, for µTP images, the ROI were chosen by excluding
the signal rising from the microbeads. The collagen portion in the ECM
space was represented by the bright pixels (Nc) in grayscale rising from the
SHG signal, while the non-collagen portion appeared as black pixels (Nb).
We define collagen fraction (CF) as the ratio between bright pixels to total
pixels in the selected ROI, as reported in Eq. 3.9:
CF =
Nc
Nc +Nb
(2.5)
where Nc and Nb represent the number of pixels from the collagen and
non collagen portion, respectively.
2.2.12 Evaluation of collagen assembly degree
The degree of collagen assembly (CAD) network was evaluated by analyzing
the intensity of the SHG signal. The analysis was performed within the µTP
space where the SHG signal was present. All SHG images were subjected
to noise subtraction and the average intensity in the two different zones was
evaluated as described by the Eq. 2.6:
CAD =
∑255
i=1 Iipi∑255
i=1 pi
(2.6)
where CAD is proportional to I the average intensity, Ii is the intensity
corresponding to the pixel pi, while the index i = xiyi runs in the gray value
interval from 1 to 255. The intensity I of collagen network is known to be
proportional to the degree of assembly of the newly synthesized collagen.
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2.2.13 Immunostaining
For immunofluorescence staining, formalin-fixed and paraffin embedded µTP
and spheroids slices were unmasked by heat antigen retrieval protocol by
citrate buffer; washed with PBS containing 0.2% Triton X-100, blocked with
FBS and 5% BSA solution and incubated with sheep anti-human Hyaluronic
acid and mouse anti-human Fibronectin. All the antibody were purchased
at Abcam (UK). Secondary antibody incubation and DAPI staining were
performed, before closing the slices with glycerol solution.
2.2.14 Statistical analysis
Data are expressed as mean ± standard deviation and show the results from
three independent experiments. Differences between groups were determined
using one-way analysis of variance (ANOVA). Significance between groups
was established for p < 0.05 after Tukey’s post test.
2.3 Results
2.3.1 Time evolution of µTP and spheroids stroma mod-
els
The µTP and spheroids models evolution was evaluated during 12 days of cul-
ture. The bright field images of the NF-µTP (Fig. 2.1 A-C) highlighted that
the size did not change during culture time, although in the spinner flask the
culture conditions promote the aggregation phenomena. The unchanged size
was due to the balance between the aggregation and contraction phenomena
caused by cells activity. Concerning CAF-µTP (Fig. 2.1 D-F) the contrac-
tion was more predominant in comparison to the aggregation phenomena,
leading to a size reduction during time. Instead for the both spheroids mod-
els, such as NF-sph (Fig. 2.1 G-I) and CAF-sph (Fig. 2.1 L-N) the final size
was the same as the initial size.
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Figure 2.1: Brightfield images of time evolution morphology of NF-µTP (A-
C), CAF-µTP (D-F), NF-sph (G-I) and CAF-sph (L-N) at day 4,8 and 12.
Fig. 2.2 reported the histological sections stained by Masson’s trichrome
of the four compared models. In particular for the both NF-µTP (Fig. 2.2
A-C) and for CAF-µTP (Fig. 2.2 D-F) was possible to distinguish the red
signal related to the microbeads, the purple signal due to the cells staining
and blue signal of the endogenous ECM. On the contrary, for both spheroids
models NF-sph (Fig. 2.2 G-I) and CAF-sph (Fig. 2.2 L-N), the Masson’s
trichrome staining showed mostly a cellular aggregate in which just few blue
pixels were detected.
In Fig. 2.3 was reported the fold change of the growth curve per unit; for
the both NF-sph and CAF-sph the cells number remained constant during
the investigate time window, in particular, as reported in the Table 2.1, they
started with 2300 ± 103 and 2400 ± 93 cells respectively at day 1, and after
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Figure 2.2: Masson’s Trichrome staining images of matrix composition evolu-
tion in NF-µTP (A-C), CAF-µTP (D-F), NF-sph (G-I) and CAF-sph (L-N)
at day 4, 8 and 12.
12 days of culture they present a final cells number of 2000 ± 116 and 1600
± 126 without any statistical difference. The NF- and CAF-µTP showed a
different trend, in particular NF-µTP started from 36 ± 7.8 cells/microbead
up to 830± 14 cells/microbead. The growth curve showed how, in this model,
between 8 and 12 days no statistical difference was detected, evidencing that
between this two time points the cells were in the stationary phase. On the
other hand, CAF-µTP started from 30 ± 1.7 cells/microbead up to 950 ± 88
cells/microbead, but in this model, the cells were still in exponential phase
(Fig. 2.3).
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Table 2.1: Cell growth in µTP and spheroids.
Type Day 1 Day 4 Day 8 Day 12
NF µTP 3.6 ± 7.8 * 101 2.3 ± 40 * 102 7.5 ± 100 * 102 8.3 ± 14 * 102
CAF µTP 3 ± 17 * 101 6 ± 70 * 101 2 ± 24 * 102 9.5 ± 88 * 102
NF spheroids 2.3 ± 103 * 103 1.1 ± 114 * 103 1.8 ± 98 * 103 2.0 ± 116 * 103
CAF spheroids 2.2 ± 93 * 103 2.4 ± 86 * 103 1.7 ± 115 * 103 1.6 ± 126 * 103
Figure 2.3: Cell number per unit (µTP or spheroids, fold change) from day
1 to day 12.
2.3.2 Metabolic activity
The Fig. 2.4 A-B showed the maximum oxygen consumption rate (Vmax)
for each model, in particular in Fig. 2.4 A the Vmax trends were reported
for the µTP models (NF and CAF); in Fig. 2.4 B the Vmax trends were
reported for the spheroids models (NF and CAF). For all models investigated
the measured trend is the same, in particular at day 4 the Vmax value was
highest respect to the next measured values, while between 8 and 12 days
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the difference of the oxygen consumption rate was less marked for spheroids
models compared to µTP models. In particular, the Vmax trend for CAF-
µTP is statistically higher than NF-µTP, the initial measured values were
8.85 * 10−8 ± 1.77 * 10−8 and 2.31 * 10−8 ± 6.15 * 10−9 respectively, while
the final values were 2.65 * 10−8 ± 7.90 * 10−9 and 3.58 * 10−9 ± 1.42 * 10−9
respectively.
Figure 2.4: Maximum rate of oxigen consumption - Vmax - over culture time
in NF- and CAF-µTP (A) and in NF- and CAF- sph (B); contribution of
H+ ions per cell in NF- and CAF-µTP (C) and in NF- and CAF- sph (D).
However, though these differences in Vmax value, were detected in µTP
models, due to the cells activities, they become undetectable in spheroids
models. Indeed the Vmax values for CAF-sph and NF-sph were not statisti-
cally different; the initial measured values were 4.01 * 10−8 ± 1.89 * 10−8 and
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4.98 * 10−8 ± 1.07 * 10−8 respectively up to 2.13 * 10−9 ± 1.01 * 10−9 and 4.69
* 10−9 ± 1.01 * 10−9 respectively as final value. The Fig. 2.4 C-D reported
the quantitative contribution of each cell to the acidification of the medium
for µTP models and spheroids models respectively; concerning the NF-µTP
model, a variation between first two time points was detectable, while no
difference reported between 8 and 12 days, and the final measured value was
8.51 * 10−16 ± 2.55 * 10−16. On the contrary, for CAF-µTP model, the
trend was always growing during time and the final value of 2.26 * 10−15 was
considerably higher than the corresponding value for NF-µTP. Furthermore,
for the spheroids models the trend was comparable with NF-µTP trend, and
in any time point no statistical differences were detected.
2.3.3 ECM composition and architecture
The analysis of the composition and architecture of the ECM was performed
at the end point (12 days of culture). In Fig. 2.5 A-D were reported the SHG
images rising from newly formed collagen signal in the NF-µTP (Fig. 2.5 A)
and CAF-µTP (Fig. 2.5 B) to NF-sph (Fig. 2.5 C) and CAF-sph (Fig. 2.5
D). SHG was used to estimate the collagen fraction (CF, according to Eq.
2.5) in the ECM that was reported in Fig. 2.5 E; concerning NF-µTP and
CAF-µTP, a statistical significance (p < 0.05) was found between quantified
values of 40% ± 11% and 54% ± 9% respectively, while, for each spheroid
model very low/no collagen fraction was detected. Furthermore from SHG
images it was also possibile to have information about the collagen assembling
degree (CAD, Fig. 2.5 F), in particular, according to Eq. 2.6, the measured
CAD was highest for the NF-µTP (18.65% ± 7.15%) and was about doubled
if compared with the CAF-µTP (10.83% ± 3.20%). As mentioned before, for
spheroids models this kind of analysis gave values close to zero. In parallel,
to evaluate the effect of matrix stiffness on NF and CAF cells biophysical
properties, MPT technique was used to probe their mechanical properties.
MSD analysis reported in Fig. 2.6 A showed that there was a significant
difference in the distance traveled by the particles probes embedded in cyto-
69
plasmic environment between NF- and CAF-µTP (8.2 * 10−5 ± 8.99 * 10−6
and 1.14 * 10−4 ± 1.99 *10−5 respectively; this difference was not detectable
for the NF-sph and CAF-sph (4.1 * 10−5 ± 1.94 * 10−5 and 3.13 * 10−5
± 1.66 * 10−5) (Fig. 2.6 B). To verify the intrinsic cellular features, NF
and CAF cells were cultured in 2D systems, on polyacrylamide matrices of
varying Young’s modulus, 3 kPa (Fig. 2.6 C) and 30 kPa (Fig. 2.6 D).
Figure 2.5: SHG (gray scale) and fluorescence (cells in red) images of NF-
µTP (A), CAF-µTP (B), NF-sph (C) and CAF-sph (D) at day 12; Collagen
fraction - CF - (E) and Collagen assembly degree - CAD - (F) in the newly
formed ECM in NF- and CAF- µTP and spheroids.
Particle tracking experiments showed that substrate stiffness modulation
significantly affects the dynamics of cell embedded tracers both in NF and
CAF. In particular, we measured MSD at τ equal to 0.1 s and the analyses
revealed that MSD decreased with increasing substrate stiffness in both cell
lines. As already said, the MSD is indirectly correlated to the mechanical
properties of intracellular environment, then the reduction of MSD on softer
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substrates was probably due to a dynamic remodeling of cytoskeleton, that
resulted to be less dense and assembled. These findings indicated that not
only NF, but also CAF cells preserved their ability to detect and respond to
the matrix elasticity, through a process known as ”stiffness sensing”.
Figure 2.6: MSD values of 500-nm diameter particles at τ equal to 0.1 s in
NF- and CAF-µTP (A), in NF- and CAF sph (B) and in NF and CAF cells
seeded on 3 (C) and 30 (D) kPa polyacrylamide substrates. The data were
presented as media ± standard error considering the number of observations
greater to 100.
To test whether CAF transformation was also reflected in their biophys-
ical properties, we compared MSD of particles embedded in NF and CAF
when the cells were on the same stiffness substrate. We found no significant
difference between MSD values of particles embedded in normal and cancer
associated fibroblasts both on 3 and 30 kPa substrates (Fig. 2.6 C-D). These
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results suggested that the activation of cancer fibroblasts was not related
to an alteration of their mechanical properties and cytoskeletal organization
and a loss of their ”stiffness sensing” ability. Thus, it is reasonable that
the measured mechanical properties of cancer and normal spheroids were not
different, because related principally to the intrinsic properties of NF and
CAF cells. In the case of µTP, we think that the mechanical phenotype of
cancer fibroblasts was changed by their ability to sense a matrix that was
softer, because of a minor content and assembly of protein components. This
evidence supported the hypothesis that the cells were responsive in terms
of cytoskeleton stiffness respect to the substrate stiffness, whereby the in-
creasing of the MSD for both µTP models was due to the presence of the
ECM. Furthermore the increase of the particles mobility corresponded to a
variation of the stiffness of the matrix, indeed the highest value was found
in CAF-µTP that presented a less assembled ECM.
2.3.4 ECM complexity
Along collagen detection, ECM components as fibronectin and hyaluronic
acid were analyzed in stromal µTP and spheroids. In Fig. 2.7 A-B the im-
munofluorescence staining showed that the fibronectin expression was higher
in CAF-µTP in comparison to NF-µTP. On the other hand, few pixels were
detected in the case of stromal spheroids (Fig. 2.7 C-D). The ratio between
fibronectin/nuclei for µTP and spheroids was highlighted in the graphic in
the Fig. 2.7 E, in particular fibronectin/nuclei ratio in NF-µTP and CAF-
µTP was 520.4 ± 331.7 and 2317.8 ± 547.4, respectively. Otherwise, fi-
bronectin/nuclei ratio in NF-sph and CAF-sph was 73.4 ± 30.7 and 225.4 ±
99.3, respectively.
Concerning hyaluronic acid, Fig. 2.8 A-B showed the different fluorescent
staining in NF-µTP and CAF-µTP. For stromal µTP, hyaluronic acid is over-
expressed in CAF-µTP rather than NF-µTP. On the other hand, there was
no difference between the expression of hyaluronic acid in NF-sph and CAF-
sph (Fig. 2.8 C-D). Fig. 2.8 E showed the values of the hyaluronic acid
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Figure 2.7: Immunofluorescence staining of Fibronectin protein (red) in NF-
(A) and CAF-µTP (B), in NF- (C) and CAF sph (D); quantification analysis
of Fibronectin obtained from immunofluorescence images (E).
pixels per nuclei in stromal µTP and spheroids. In particular the ratio of
hyaluronic acid pixels per nuclei was 636.3 ± 276.7 and 3861.8 ± 719.7 for
NF-µTP and CAF-µTP, respectively, while it was 225.2 ± 99.3 and 262.70
± 143.7 for NF-sph and CAF-sph, respectively.
2.4 Discussions
In this work, NF and CAF cells were used to create two kinds of 3D mod-
els: microtissues and spheroids. µTP were fabricated by seeding each cell
line within gelatin porous microbeads. In a previous work, we have al-
ready demonstrated that the interactions among fibroblasts and microscaf-
folds triggered mechanotrasduction pathways involved in collagen remodeling
[6]. Consequently, fibroblasts synthesize new collagen molecules and remod-
eled their microenvironment [6]. Spheroids are cellular aggregates largely
used to simulate 3D architecture of solid tumor better than the conventional
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Figure 2.8: Immunofluorescence staining of Hyaluronic Acid protein (red) in
NF- (A) and CAF-µTP (B), in NF- (C) and CAF-sph (D); quantification
analysis of Hyaluronic Acid obtained from immunofluorescence images (E).
monolayer cell culture [90]. Arranging the cells in these two 3D models, dif-
ferent behaviors in terms of metabolic activity, mechanical properties and
ECM remodeling were detected. Indeed, the 3D environment in which the
cells grow, plays a crucial role in maintaining their own characteristics, and
the different architecture of the model gives back different global features.
In terms of size, spheroids, independently from the cells used to build up
the model, present a low contraction capability; indeed the cells are closely
arranged and engaged in intercellular membranes contacts and cell-cell junc-
tions [86]. On the other hand, for µTP models, the contraction phenomena,
related to force generation, migratory behavior, focal adhesion formation and
cytoskeleton organization are evident. In particular the highest contraction
is detectable in CAF-µTP model, in which the activated cell contraction is
governed, as in tumor connective environment, by the balance between four
biophysical processes: generation of contractile forces, transmission of the
contractile forces via integrins to the surrounding extracellular matrix, the
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cytoskeleton remodeling, and enzymatic degradation of the matrix network
[37]. The spheroids, due to their structure, do not present an increasing of
the total cells number, indeed, despite a consistent number of cells of the
more external layer were under duplication cycle, the replacement occurs
through the expulsion of the cells that migrate outside the model. On the
contrary, the µTP are made starting from few cells that are able to duplicate
themselves, and the microbeads surface allows the proliferation without re-
placement. Furthermore, the different nature of the used cells (NF and CAF)
means two different trends; in particular the CAF cells retain the greater
proliferative capability such as tumor associate cells in vivo [91]. From the
metabolic point of view, the oxygen consumption rate of the CAF-µTP result
constantly higher than NF-µTP, probably due to the evidence that in tumor
activated cells, the metabolic pathways in which the oxygen is a substrate,
are faster than health cells (i.e. duplication, nucleotide synthesis, migration,
fatty-acid synthesis) [92]. Moreover, the tumor cells produce ATP molecules
not by oxidative phosphorylation, but by glycolysis pathway also in the pres-
ence of abundant oxygen, a phenomenon known as aerobic glycolysis or the
”Warburg effect” [82]. This metabolic pathway is 16 times less efficient than
oxidative phosphorylation, but 200 times faster, indeed in the time unit leads
to obtain 13 times more ATP molecules. Our results correlate with recent
findings reporting the higher consumption of glucose in CAF rather than
normal fibroblasts, as well as the increased production of lactate. Recent
evidences introduced the new idea, anmely ”Reverse Warburg Effect”, sug-
gesting that aerobic glycolysis may be performed by cancer associated fibrob-
lasts, reather than by epithelial cancer cells themselves [93]. Interestingly,
previous metabolic studies with skin myofibroblasts have demonstrated that
they perform aerobic glycolysis, with increased glucose uptake and lactate
secretion, suggesting that the ”Reverse Warburg Effect” may be a general
feature of both myofibroblasts and CAF [94]. Since CAF seems to be deputed
to the metabolic request and the cancer cells activated the normal stroma,
turning it into a factory for the production of energy-rich metabolites for
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cancer progression and angiogenesis, it became important to replicate tumor
model in vitro where the fibroblastic stromal component is not negligible. In
this scenario, lactate secretion released in the extracellular space leads to an
acidification of the environment that can be considerate an indirect proof of
the metabolic activity a powerful predictive biomarker for recurrence, metas-
tasis and poor clinical outcome [95]. Again, our stroma model, both normal
and tumoral, is able to maintain the pathophysiological differences founded
in vivo and used as model for the study of tumor progression or as a tool for
drug testing. In our results we have shown how a difference between health
ad cancer activated fibroblasts was detectable only in µTP configuration; as a
consequence we can deduce that, although phenotypically different, the cells
are no longer able to reproduce in vivo phenomena in spheroid model. It
has already known that cells immediately adjacent to a tumor were no more
considered a passive structural element. Indeed, recent studies assessed that
contrary to being an idle spectator, the surrounding microenvironment, ac-
tively contributes to tumor progression. Furthermore, tumor progression is
sustained by a reciprocal paracrine loop between CAF and cancer cells. Can-
cer cells trigger the fibroblast-activated phenotype which, in turn, produces
a series of growth factors and cytokines that sustain tumor progression by
promoting ECM remodeling, cell proliferation, angiogenesis and EMT. On
the basis of evidence reported in this work, we could assess that only a 3D
model as µTP that take into account the presence of endogenous ECM, with
regulatory functions could recapitulate the real microenvironment, both in
physiological and pathological features. In this context the ECM plays a
pivotal role, indeed only in the µTP models the cells are engaged in ECM
remodeling phenomena. In spheroid model, although there are the ECM pro-
teins, they are much less expressed than µTP and non-correctly assembled.
This substantial difference between these two models has an impact also
in cellular mechanical properties, in particular the MSD results show how,
only in µTP configuration, the cells are able to change their own mechani-
cal properties in relationship to the different assembly degree of the ECM.
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In particular, CAF-µTP present an ECM less assembled and consequently
the MSD are higher than NF-µTP, indicating a less structured cytoskeleton
[96]; on the contrary, the NF structure their cytoskeleton respect to a hard
substrate (more assembled ECM). These findings demonstrated how the dif-
ferent organization of ECM in µTP configuration influences the mechanical
properties of cells [97]. Our results demonstrate how, arranged in spheroids
architecture, the cells show the same MSD value, this represent a strong
limitation for this model that worse replicate the in vivo environment and
depress the morphological and metabolic differences between the NF and
CAF. Collagen, primarily type I collagen, is capable of producing an SHG
signal that can be detected in biological samples and used as a technique for
monitoring the changes in ECM structure throughout tumor development
[13]. Collagen I is a peculiar marker for fibrosis in several type of cancer and
we are able to fabricate 3D µTP where collagen is over expressed by CAF in
comparison to NF. However we cannot support the 3D spheroid model that
do not show the SHG signal for Collagen I. In order to validate the ECM
features and the difference between normal and tumoral stromal 3D model,
we decided to analyze as the expression of fibronectin and hyaluronic acid,
two relevant ECM components. These ECM components have been shown
to be over-expressed in tumor microenvironment. Fibronectin can be a lig-
and for several integrins and regulates collagen fibril structure; moreover, its
expression has been associated to tumor metastatic potential and MMP se-
cretion, playing important roles in cell adhesion, migration and growth [31].
CAF mediated the overexpression of hyaluronic acid within the tumor mi-
croenvironment, and played a role in the recruitment of cancer-associated
macrophages, which are key regulatory cells involved in cancer angiogenesis
through endothelial cell recruitment [16]. Moreover, as previously reported,
tumor cells prefer anaerobic metabolism and generate lactate, even in the
presence of oxygen. Lactate could induce fibroblasts to deposit hyaluronan
and to express CD44, thereby participating in the process of cancer invasion
and metastasis [98]. The right modulation of these ECM proteins in µTP but
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not in spheroid models, made the former a valuable tool for the recapitula-
tion of in vivo microenvironment. Indeed in µTP fibronectin and hyaluronic
acid not only were expressed and organized within the ECM but also were
over-expressed in CAF-µTP, resembling the tumor microenvironment. Thus,
cancer cannot be considered as a result of deregulation of intracellular sig-
naling pathways, because ECM exerts a regulatory activity on cell fate and
the pathological derailment that leads to cancer transformation. Due to the
relevant and essential role of ECM in tumor progression it become necessary
fabricate tumor model that take into account the role of the ECM and stroma
cells in terms of metabolism, mechanical properties and ECM composition in
order to validate new therapeutics or study the tumor growth and metastasis.
2.5 Conclusions
In this work normal and tumoral microtissues were compared to the respec-
tive spheroids. Different behaviors in terms of metabolic activity, mechanical
properties and ECM remodeling were detected. In particular, only in µTP
configuration, we found differences between normal and activated fibrob-
lasts. From the metabolic point of view, only when CAF are present in µTP
configuration, show an alteration in metabolic energy compared to normal
counterparts. Furthermore only in µTP model the stromal cells are able to
produce and synthesize endogenous ECM that has an impact also in cellular
mechanical properties. In spheroid model, although there are the ECM pro-
teins, they are much less expressed than µTP and non-correctly assembled.
Therefore although phenotypically different, the cells are no longer able to
reproduce in vivo phenomena in spheroid model. These findings represent a
strong limitation for spheroid model that worse replicate the in vivo environ-
ment and depress the morphological and metabolic differences between the
NF and CAF. On the basis of evidence reported in this work, we can assess
that the µTP model is adaptable as a valuable tool for the recapitulation of
tumor microenvironment in vitro.
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Chapter 3
On-line monitoring of transport
properties and ECM
remodelling of tumor activated
stroma in a chip
3.1 Introduction
Tumor microenvironment and its interactions with cancer cells plays an es-
sential roles in tumor progression and metastasis [99]. Stroma and extra
cellular matrix (ECM) represent a pivotal and dynamic elements of such
tumor microenvironment [31]. Indeed, tumor stroma orchestrates the in-
teractions rising among such different cell types and, in turn, undergoes
several alterations during tumor cell migration and invasion [100]. To date,
one of the most relevant weaknesses of the in vitro tumor models is the non-
recapitulation of the ECM-associated dynamics featuring the tumor microen-
vironment, during tumor progression. One of such ECM-associated dynamics
concerns the ECM remodeling itself, occurring when tumor cells invade the
surrounding stroma. As tumor evolves, the stroma undergoes a transition
from ”healthy” to ”activated” status, changing its architecture, composition
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and transport properties aiding the tumor progression by means of a reci-
procity mechanism [31], [43]. Due to its active role in cancer progression and
invasion, tumor stroma and its mutation during tumorigenesis, are becoming
one of the main target in cancer therapy [101], [102]. The lacking of reliable
in vitro model prevents the opportunities to investigate and therapeutically
target such clinically relevant pathological target. Indeed, tumor response in
vitro is still studied basically at cellular level [59], making the animal models
the only milieu in which stroma modification can be taken into account [103].
To date, two-dimensional (2D) monolayer and three-dimensional (3D) model
(spheroids, cell-populated biomatrices) have been extensively used as tumor
model in vitro [43], showing several limitations. In particular, in 2D systems
and 3D spheroids the most relevant biological interactions are restricted to
cell-cell interactions while the cell-ECM ones result almost absent. At last,
cells embedded in 3D gel of ECM-derived biopolymers (i.e. collagen, Ma-
trigel) have the advantageous in that the ECM composition and cell types
can be tailored to the disease under investigation; nevertheless, due to their
exogenous character fail in replicating both the structural and the morpholog-
ical changes occurring during pathologic events [104]. For this reason both
on line and off line extrapolation of the architectural, morphological and
other physical parameters concerning the ECM modification is denied. The
stroma evolution can be currently detected only in xenograft animal models
coupled with non-invasive optical techniques such as multiphoton microscopy
or optical coherence tomography [61], [105], [106]. On the other hand, an-
imal models exhibit significant drawbacks including cost, time consuming,
unpredictable characteristics and difficulty in correlating observed results
with human responses [59], [60]. In this scenario microfluidic technology has
enabled the development of promising in vitro platforms that address the
challenges of reconstituting, integrating, and interrogating many variables of
the tumor microenvironment [59]. Microfluidic devices can be fabricated in a
compartmentalized fashion creating cell-cell interfaces recapitulating specific
cellular cross talk, under controlled laminar flow [59]. Furthermore, they
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enable studying of complex phenomena such as drug distribution and pene-
tration [107], [57] or vascular network growth / ingrowth in 3D matrices [108].
Additionally, optical accessible microdevices enable in situ imaging of living
cultures with high spatiotemporal resolution [109], [110]. In this direction,
several studies have incorporated the aforementioned in vitro model in the
microfluidic device to simulate the complex stroma-cancer relationship [59],
[60], [109], [111] and evaluate the efficacy of potential therapeutics against
cancer pathology [57], [59], [60], [112]. With the aim of measuring in real
time the ECM dynamics associated to the stroma activation, in this work
we replicated the cross-talk between epithelial tumor and the surrounding
stroma in a chip. The optically accessible microfluidic chip hosted two com-
partments for accommodating stromal and tumor microtissues respectively,
separated by an interface that allows their physical contact. The 3D stro-
mal microtissues are composed by an engineered system in which fibroblasts
are continuously engaged in synthesizing, assembling and disassembling their
own ECM [51], [113]. The combination of such innovative 3D microtissues
with microfluidic technology, allowed us to detect in real time the modifica-
tion occurring at ECM level via confocal and multiphoton microscopy. We
found that the stroma tissue underwent the same modification found in vivo
at both cellular and extracellular level. In particular, it was investigated
the production of hyaluronic acid and fibronectin; the real time investigation
of both collagen network architecture and the related variation of the diffu-
sion coefficient by in situ fluorescence recovery after photobleaching (FRAP)
technique.
I
3.2 Materials and Methods
3.2.1 Microfluidic device design and fabrication
An optical accessible microfluidic device was designed by means of computer-
aided design software. It was conceived in order to allow the culture of 3D-
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µTP under dynamic flow conditions. Fig. 3.1 shows the configuration of the
microfluidic device composed of two chambers (inner/tumor chamber 370 x
780 x 300 µm and outer/stromal chamber 1200 x 1370 x 300 µm) for 3D-µTP
accommodation, separated by arrays of regularly spaced posts (120 x 120 x
300 µm).
Figure 3.1: Schematic representation of the microfluidic device for 3D mi-
crotissue loading. The microfluidic system is composed of two chambers for
tumor and stromal µTP accommodation and two lateral media channels.
The two chambers were provided by a dedicated channel for loading 3D-
µTP (200 x 4000 x 300 µm and 400 x 4000 x 300 µm for tumor and stromal
loading respectively), while the other two lateral channels (500 x 1800 x 300
µm) allowed the culture medium to flow guaranteeing nutrient supply and
waste removal. Before fabrication, the file CAD was converted into file CAM
using DESKAM software. The microfluidic device was created by replica
molding technique. The master was carved onto a Poly(methyl methacry-
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late) (PMMA, Goodfellow) slab with a micromilling machine (Minitech CNC
Mini-Mill). Polydimethylsiloxane PDMS (Sylgard 184, Mascherpa) base and
curing agent were mixed thoroughly in the weight ratio 10:1, degassed under
vacuum for 20 minutes in order to remove unwanted air bubbles. Then the
liquid PDMS was carefully poured on PMMA master and cured in an oven
for 1 h at 80◦C. After cooling, the PDMS layer was gently peeled off from the
master. Inlet and outlet holes were made by punching through the PDMS
with a 1.5 mm and 2.5 mm biopsy punch (DifaCooper) for chambers and lat-
eral channels, respectively. The PDMS layer and a coverslip (Menzel-Glaser
24 x 60 mm, # 1.5) were bonded by oxygen plasma treatment for 1 min at
50 W in an oxygen plasma oven (Plasma Femto, Diener). After the plasma
treatment the device was maintained at 80◦C in the oven for at least 1 h to
strengthen the bond.
3.2.2 Stromal and tumor 3D-µTP production
Cell line
Normal mammary fibroblasts (NF) and cancer associated fibroblast (CAF),
kindly donated by Kojima’s group, were sub-cultured onto 150 mm Petri
dishes in Dulbecco’s Modified Eagle Medium with high glucose, containing
10% fetal bovine serum, 100 µg/ml L-glutamine, 100 U/ml penicillin/ strep-
tomycin. Human breast adenocarcinoma cells (MCF7) were kindly donated
by Daidone’s group and sub-cultured in RPMI-1640 (Roswell Park Memorial
Institute) medium supplemented with 10% fetal bovine serum, 100 µg/ml
L-glutamine, 100 U/ml penicillin/ streptomycin. Cells were maintained at
37◦C in humidified atmosphere containing 5% CO2. Fibroblasts were stable
transfected with pLVX-DsRed-express2-N1 (ˆIex 554nm, λem 591nm) vi-
ral vector, while MCF7 cells were transfected with pLVX-ZsGreen1-N1 (λex
493nm, λem 505 nm). Viral vector were purchased at Clontech, USA. Three
kinds of µTP were produced: NF-µTP, CAF-µTP and MCF7-µTP. For 3D-
µTP production three dynamic spinner cultures in parallel were performed
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by seeding NF, CAF or MCF7 cells on gelatin porous microcarriers (GPMs)
as previously reported [6].
Microscaffold production
The microscaffolds were produced by following a previously established pro-
tocol [6]. For the of this work microscaffolds at 5% w/w of crosslink have been
used to perform all the experiments. Before using, dry microscaffolds were
sterilized in absolute ethanol 24 h on a rotating plate. Then, microscaffolds
were washed twice in sterile phosphate-buffered saline (PBS) without calcium
and magnesium solution. Finally, before cell seeding, PBS was replaced with
fresh culture medium.
3D-µTP production
Spinner flask bioreactors were used to fabricate 3D-µTP. For each spinner
culture 50 mg of microscaffolds were loaded together with 7.5 x 105 cells
corresponding to an initial ratio of 30 cell/microscaffold for each cell line
(NF, CAF or MCF7). To help cell seeding on microscaffold an intermittent
stirring regime (30 min at 0 rpm, 5 min at 30 rpm) for 6 h has been performed.
Then, dynamic cultures were kept under continuous stirring at 30 rpm for
up to 12 days. Medium was changed on the first day and every 3 days until
the end of the experiments. Ascorbic acid (final concentration 50 µg ml−1)
was added to each spinner culture from day 2.
3.2.3 Tumor-on-chip culture
Device preparation
Before using, the device was sterilized by dipping into pure ethanol and
after into PBS (supplemented with 2% of penicillin/streptomycin) in order
to remove residual ethanol. The device was placed under UV light for 30 min.
Tygon tubes (CM Scientific, UK, ID 1/16”) were inserted into the inlets and
outles of the lateral channels using an interface of male luer lock connectors
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attached to barbed female luer lock connectors (Harvard Apparatus). Tubes
and connectors were sterilized previously in autoclave. The flow assembly was
set up using 1 and 3 ways stopcocks (Harward Apparatus). The stopcocks
were sterilized in ethanol and washed in PBS. Before 3D-µTP loading, a 5
ml syringe filled with medium was connected to the inlet stream of one side
channel in order to fill the channels with medium.
3D-µTP loading
The 3D-µTP suspensions were injected in the corresponding chamber using
a simple pipette-driven loading process. We prepared three different device
configurations:
• NF-µTP, obtained by loading NF-µTP in the stroma chamber and kept
from T0 (0 h) to T2 (48 h);
• CAF-µTP, obtained by loading CAF-µTP in the stroma chamber and
kept from T0 (0 h) to T2 (48 h);
• Activated-NF-µTP (AC-µTP), obtained by loading NF-µTP at time
T0 (0 h) and then loading MCF7-µTP at T1 (24 h) and kept up to T2
(48 h).
All the experiments were repeated in triplicate. Once the chamber was
filled, the inlet and outlet of the chambers were closed with a 250 µm PDMS
membrane (realized with spin coater 500 rpm for 30 s), a gate for medium
outflow was opened in the opposite direction and the syringe pump was
started (Harward Apparatus). A nominal flow rate of 3.0 µl min−1 producing
an average linear velocity similar to that of blood in tumors was performed
2. The device was placed inside a 37 ◦C incubator with 5%CO2 and 95%
relative humidity for 48 h. The microfluidic device was observed daily by an
inverted optical microscope.
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3.2.4 In situ and on line tissue imaging
Immunofluorescence staining, imaging and quantification
α-sma, PDGFRβ-r, MMPs, Fibronectin and Hyaluronic Acid Imag-
ing
Immunofluorescence assays were performed directly in the microfluidic device
to detect α-SMA, PDGFβ-r MMP-9, MMP-2, fibronectin and hyaluronic acid
in the stromal chamber of microdevice. To perform the immunofluorescence
assay, at the end of the experiment (T2, 48 h) a washing solution of PBS
was flew in the devices for 50 min (5 µl min−1); then 4% Paraformaldehyde
was flew for fixing for 20 min, and then in PBS washing solution for 50 min.
Subsequently the permeabilizing solution (0.2% Triton X-100 + 3% BSA +
PBS) was injected with syringe pump for 50 min and blocked for 2 h. Then
primary antibody (fibronectin 1:400, hyaluronic acid 1:50, MMP-9 1:200,
MMP-2 1:100, α-SMA 1:250 and PDGFβ-r 1:200, Abcam) was introduced
in the device. After overnight incubation, it was introduced in sequence
PBS for 50 min, 0.2% Triton X-100 + PBS for 50 min, secondary antibody
(Alexafluor) for 90 minutes. Finally a slow flow of PBS for 1 h was used to
wash the tissues in the device.
α-sma, PDGFRβ-r, MMPs, Fibronectin and Hyaluronic Acid quan-
tification
The amount of MMPs, Fibronectin and Hyaluronic Acid in the new formed
ECM, was obtained processing the corresponding fluorescent images. After
threshold in ImageJ, it was quantified the fraction of fluorescence signal in
different regions of interest (ROI). In the same ROI, it was evaluated total
cells number by counting their nuclei. Finally, it was evaluated the fraction
of signal per cell [114].
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On-line imaging and quantification
Collagen network imaging
Two-photon excited fluorescence (Leica TCS SP5 II coupled with a Multi-
photon Microscope Chamaleon Compact OPO-Vis, Coherent) has been used
to induce Second Harmonic Generation (SHG) and obtain high-resolution im-
ages of unstained collagen structures in the ECM of NF- and CAF-µTP (λex
= 840 nm and λem = 420 ± 5). Images of 1024 x 1024 pixels and eight SHG
z-stacks (10-15 µm step size) were acquired along the length of the stroma
chamber under identical conditions (objective 25X/0.95 NA water immer-
sion) and laser power (90 mW). The SHG stacks were then z-projected using
a maximum intensity approach. The acquisition were performed as follow:
• NF-µTP and CAF-µTP were imaged at T0 (4 h after loading), T1 (24
h after loading) and T2 (48 h after loading);
• AC-µTP, were imaged at T0 (4 h after NF-µTP loading), T1 (4h after
MCF7-µTP loading) and T2 (48 h after T0).
Collagen network quantification
In order to quantify the collagen fraction in the endogenous ECM of the stro-
mal tissues, SHG images were analyzed by using ImageJ software. Selected
ROI were chosen by excluding the signal rising from the microscaffold. The
collagenous portion in the ECM space was represented by the bright pixels
(Nc) in grayscale originating from the SHG signal, while the non-collagenous
portion appeared as black pixels (Nb). We define the collagen fraction (CF)
the ratio between bright pixels to total pixels in the selected ROI, as reported
in Eq. 3.1:
CF =
Nc
Nc +Nb
(3.1)
where Nc and Nb represent the number of pixels from the collagen and
non collagen portion, respectively. Moreover, to quantitatively assess the col-
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lagen related changes, we perform Gray-level Co-occurrence Matrix (GLCM)
texture analysis, using the ImageJ plug-in ”Texture” on SHG images [104].
The GLCM was formed by counting the number of occurrences of a gray
level adjacent to another gray level, at a specified pixel distance and direc-
tion. In particular, we calculated the correlation feature (Cor), a measure
of intensity correlation as a function of pixel distance. The correlation was
calculated for distances ranging from 1 to 16 µm in the horizontal (0◦) and
vertical (90◦) direction. The Eq. 3.2 of Cor is given as below [63]:
Corr =
∑
i,j
(i− µi)(j − µj)p(i, j)
σiσj
(3.2)
where µi, µj, σi and σj are given by:
µi =
∑
i,j
ip(i, j) (3.3)
µj =
∑
i,j
jp(i, j) (3.4)
σi =
√∑
i,j
(1− µi)2p(i, j) (3.5)
σj =
√∑
i,j
(1− µj)2p(i, j) (3.6)
In particular p(i,j) is the probability of gray level i occurring next to gray
level j, µi, µj, σi and σj are the means µ and standard deviations σ of column
i and line j of the matrix, respectively [103]. All parameters have a maximum
value of 1 and a minimum value of 0 or -1 [103]. The Cor curve is an index
of the architecture of the network, with a fast decay for fine textures and
slow decay for coarse structure. From the Cor curve it is possible to obtain
the correlation length λ, defined as the distance at which the Cor decay is
equal to 0.5. Lower is λ finer is the texture. At last we analyzed SHG images
to calculate the Collagen Assembly Degree (CAD) of collagen network [115].
To this purpose, all SHG images were subjected to noise subtraction and the
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average intensity in the two different zones was evaluated as described by the
Eq. 3.7:
CAD =
∑255
i=1 Iipi∑255
i=1 pi
(3.7)
where I the average intensity, Ii is the intensity corresponding to the
pixel pi, while the index i = xiyi runs in the gray value interval from 1 to
255. The intensity I of collagen network is known to be proportional to the
degree of assembly of the newly synthesized collagen [115], [116], [110].
3.2.5 On-line measurement of the transport properties
The transport properties of the neo-formed tissues were measured in the
devices, by means of real time application of Fluorescence Recovery After
Photobleaching (FRAP) technique [117]. 3 kDa FITC-Dextran solution (5
µg ml−1 in Dulbecco’s Modified Eagle Medium with high glucose, contain-
ing 2% fetal bovine serum, 100 µg ml−1 L-glutamine, 100 U ml−1 penicillin /
streptomycin) was overnight flew in the devices at 3 µl min−1 and 37◦C before
the experiments. Prior to perform the FRAP experiments, ROI containing
neo-formed collagen were detected by using SHG signal. Then, the FRAP
measurements were conducted with a laser scanning microscope (TCS SP5,
Leica). Samples were illuminated with a 25X (NA 0.95) objective and 488
nm excitation line from Argon laser operating with 5% output power. The
bleaching time was 5.16s and the total ROI fluorescence images after photo-
bleaching were collected at intervals of 0.263s at 512 x 512 pixel resolution
using a pinhole of 600 µm, zoom factor 2.5 (with a zoom-in during bleaching)
and 1000 Hz. Briefly, the mean fluorescence in the bleached region over time
was converted to normalized fractional fluorescence intensity [118] (Eq. 3.8
f =
Ft − F0
F∞ − F0 (3.8)
where Ft is the fluorescence intensity at time t, F0 is the fluorescence
intensity immediately after bleaching, and F∞ is the fluorescence after com-
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plete recovery. The normalized fractional fluorescence intensity was plotted
versus time and fitted with an exponential curve. The equation of curve was
used to determine the half-recovery time (τ) at f = 0.5. Finally, the diffusion
coefficient can be calculated as follow (Eq. 3.9:
D =
ω2
4t
(3.9)
where ω is the initial spot radius.
3.2.6 Statistical analysis
The differences between two or more groups were evaluated (pvalue ¡ 0.05)
using one-way analysis of variance (ANOVA). A Gaussian distribution for
each population was assumed. For pair-wise comparisons within each exper-
imental group, Tukey’s post test was used.
3.3 Results and Discussions
3.3.1 Breast cancer microenvironment on chip
In this work, an optically accessible microfluidic device was designed for
the real time monitoring of the phenotypic, morphological and transport
changes occurring in the healthy stroma (NF-µTP) activated by the inter-
action with epithelial breast tumor microtissues (MCF7-µTP). To replicate
the tumor microenvironment the device was conceived in order to guaran-
tee both compartmentalization and interaction between stromal and tumoral
tissue allowing the imaging of distinct regions (Fig. 3.1). The geometrical
configuration has been chosen to better recapitulate the in vivo pathophysio-
logical conditions, where cancer cells are confined to the ductal system of the
breast surrounded by stromal cells [107]. Cells in vivo are physically orga-
nized in 3D patterns surrounded by other cells as well as ECM that provide
physical support and signaling molecule. The co-culture carried out in the
microfluidic device presents the prominent advantage to recreate the dynamic
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tumor-stroma cross talk, crucial in tumor development. For each experiment
three microfluidic devices were performed in parallel: two microdevices were
loaded with stromal-tissue, NF-µTP (Fig. 3.2 A) and CAF-µTP (Fig. 3.2 B)
respectively; the third device was used for co-culturing NF-µTP and MCF7-
µTP (Fig. 3.2 C).
Figure 3.2: Bright field images of the stromal and tumor chambers containing
NF-µTP (A), CAF-µTP (B) and AC-µTP (obtained by loading NF-µTP at
time T0 and then loading MCF7-µTP at T1) after 48 h of loading (T2). D:
fluorescence images of NF-µTP (in red) and MCF7-µTP (in green). Time-
lapse images of MCF7 and NF-µTP after 4 (E), 8 (F), 12 (G) h of MCF7-µTP
loading. Scale bar = 100 µm.
In Fig. 3.2 A-C, the bright field images of all loaded microdevices at
T2 were reported, showing the µTP well packed in the dedicated chambers.
In the microdevice dedicated to co-culture, NF-µTP and MCF7-µTP were
in contact along the array of pillar separating tumor and stromal chamber.
Since the NF and MCF7 were clearly distinguishable due to their intrinsic
fluorescence (Fig. 3.2 D), it is possible to observe in real time invasion of
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tumor cells towards the adjacent chamber (Fig 3.2 E). Just after 8 hours it
is possible to observe single tumor cells that left the MCF7-µTP to migrate
towards the stromal chamber where NF-µTP were accommodated (Fig 3.2
F), after 12 hours the numbers of tumor cells invading the stromal chamber
increased (Fig. 3.2 G). These results are in agreement with previous works
demonstrating that fibroblasts arranged in a 3D configuration induced the in-
vasive behavior of tumor cells. This was due also to the increase of paracrine-
signaling molecules occurring in 3D compared to 2D cultures [119]. In our
experiments a syringe pump controlled the flow rate in the microfluidic device
and the entire setup could be readily accommodated on the microscope stage
in a climate-controlled incubator. By using such configuration, nutrients and
eventual therapeutics can easily reach the cells of 3D-µTP via continuous
perfusion of the medium and, at the same time, metabolic wastes can be
removed. Recently, several studies have combined microfluidic techniques
with 3D tumor models, like spheroids, to better recapitulate tumor microen-
vironment found in vivo. However, spheroids only partially recapitulate the
tumor complexity seen in vivo because due to the lack of a controlled mi-
croarchitecture and a significant presence of ECM components. As previously
described [51], [113], the 3D-µTP model used in this work, can represent a
more realistic tool to recapitulate the ECM dynamic in vitro. Indeed in such
configuration the fibroblasts are engaged in the ECM turnover: assembly and
disassembly of collagen, elastin and hyaluronic acid [113]. The presence of
such condition in the tumor stroma is crucial in the in the effort of mimicking
the behavior of some tumor types featured by a dense desmoplastic stromal
reaction like breast adenocarcinoma [120]. For these reasons, the integration
of the engineered 3D-µTP within the microfluidic device will offer a novel
tool to investigate cancer progression at both cellular and ECM level.
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3.3.2 MCF7-µTP induces NF-µTP activation at cellu-
lar and ECM level
Phenotypic activation and MMPs over-expression in activated tis-
sues
Firstly, we investigated if a period of 24 h of co-culture of MCF7-µTP and
NF-µTP in the microfluidic device could activate the NF and turn them
into myofibroblasts. It is well known that one of the major marker proteins
to identify myofibroblasts is α-SMA [121]. In addition, there are several
observations suggesting that the presence of PDGF receptors in stromal cells
is an important indicator of the desmoplastic reaction in tumors [122].
Figure 3.3: α-sma and PDGFβ-r fluorescence images (red signal) in NF-µTP
(A, D), CAF-µTP (B, E) and AC-µTP (C, F). Green fluorescence is related
to cells. Scale bar = 50 µm.
For this reason, the over-expression of PDGF receptors in breast tumors
is recently correlated with tumor progression and invasion becoming a novel
drug target [123]. As consequence, in addition to α-SMA we identified PDGF
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receptors as markers of NF activation and we performed immunofluorescence
analyses to reveal their presence directly in the microfluidic devices. The
results of immunofluorescences at T2 are reported in Fig. 3.3 and showed
that as expected, CAF-µTP (Fig. 3.3 B and E) were positive for both α-SMA
and PDGFβ-r (red signal in pictures) while at the same time point NF-µTP
did not express the proteins (Fig. 3.3 A and D). In contrast, in co-culture
conditions immunofluorescences reveal the presence of both the proteins in
the NF-µTP, suggesting that the co-culture with MCF7-µTP induced the
activation of NF into myofibroblasts generating the AC-µTP. These data
are in agreement with previous works that have demonstrated the activation
of normal fibroblasts into myofibroblasts after their physical contact with
cancer cells in a microfluidic device [124].
In addition we further investigated the expression of MMPs (Fig. 3.4),
enzymes responsible for matrix degradation that have been shown to play a
significant role in tumor progression [125], [126]. Indeed, the ability of cancer
cells to migrate through 3D environments likely depends on their possibility
to stimulate fibroblasts in the production of MMPs in a paracrine fashion.
The over-expression of MMPs in the tumor microenvironment is often asso-
ciated with adjacent normal tissues rather than the tumor cells themselves,
suggesting that neoplastic cells can use MMPs produced by normal cells to
facilitate their invasion and progression [127]. Among MMP family, MMP-9
and MMP-2 are known to play an important role in the context of tumorigen-
esis and metastasis, especially in breast tumor, because they degrade collagen
IV and weaken the basement membrane. Degradation products of ECM, in-
cluding fragments of collagen IV, can act as signaling substances regulating
tumor cell motility [128]. We found an over-expression of MMP-9 and MMP-
2 in CAF-µTP (Fig. 3.4 B and E) compared to NF-µTP (Fig. 3.4 A and
D), while AC-µTP (Fig. 3.4 C and F) showed an over-expression of MMP-9
(Fig. 3.4 G) but not of MMP-2 (Fig. 3.4 H). Previous works reported that
depending on the culture-system, co-culturing tumor-derived or normal fi-
broblasts with breast cancer cells should result in an increased expression of
94
Figure 3.4: MMP-9 and MMP-2 fluorescence images (red signal) in NF-µTP
(A, D), CAF-µTP (B, E) and AC-µTP (C, F). Green fluorescence is related
to cells. Scale bar = 75 µm. Quantification of MMP-9 (G) and MMP-2
(H) expression (pixels / nuclei) in NF-µTP (light gray), CAF-µTP (middle
gray) and AC-µTP (dark gray). Whiskers and asterisks indicate statistical
difference with p < 0.05.
MMP-2 by either partner [128]. In particular, the co-culture of the breast
cancer cells and fibroblasts resulted in an increase of MMP-2 in culture su-
pernatants in a manner that was largely, although not entirely, dependent on
direct contact between the two cells types [129], [130], [131], [132]. However,
this process has only been demonstrated when the co-culture was carried for
more than 2 days [129]. In our case, the compartmentalization created by
pillars between the stroma and cancer chambers in the microfluidic device
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allows the physical contact among the cells but the time of contact (24 h) is
probably not enough to induce MMP-2 over-expression in the AC-µTP. Re-
garding MMP-9 expression, our data are in accordance with previous findings
in vitro showing the increased production of MMP-9 in the co-cultivation of
fibroblasts and breast cancer cells after 24 hours of cell contact in a Boyden
chamber [133]. In conclusion these results suggest that although MMP-2 and
MMP-9 are both gelatinase, the time needed to record their overexpression
in stromal cells in contact with tumor cells is different. This aspect can seem
controversial but can be explained by the fact that their trigger mechanism
is probably different [132].
3.3.3 ECM components over-expression in activated
tissue
To better understand the dynamic nature of the 3D microenvironment sur-
rounding cells, it is mandatory to have a tissue model in which the cells
are embedded in a 3D matrix. As ECM surrogates, collagen and other
biopolymers partially recapitulate the whole tissue dynamics. Indeed, we
have demonstrated that the mechanism of tissue remodeling in terms of syn-
thesis, assembly and degradation of the ECM are depressed in cell-populated
collagen gels [104]. Only engineered tissues composed by cells embedded in
their own ECM are able to replicate in vitro the pathophysiological process
occurring in vivo at extracellular level. This condition allows to monitor and
to quantify the active modification of the ECM composition and organization
due to the progression of pathologic status [44], [104]. To this end, we in-
vestigated the evolution of the keys ECM components involved in the tumor
process, such as fibronectin, hyaluronic acid (HA) and collagen (Fig. 3.5).
It is well known that the abnormal structure and function of tumor stroma
is largely attributed to the up-regulation and re-organization of matrix re-
modeling molecules [126]. For example, a significant number of studies show
that HA and fibronectin deposition increase in various types of cancer tis-
sues including breast cancer, and the rate of HA synthesis is much higher in
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Figure 3.5: Fibronectin fluorescence images (red signal) in NF-µTP (A),
CAF-µTP (B) and AC-µTP (C). Scale bar = 100 µm. Hyaluronic Acid
fluorescence images (red signal) in NF-µTP (D), CAF-µTP (E) and AC-
µTP (F). Scale bar = 75 µm. SHG signal (gray scale) from newly formed
fibrillar collagen in NF-µTP (G), CAF-µTP (H) and AC-µTP (I). Scale bar
= 50 µm.
cancers than in normal tissues [16]. Unlike studies in which the presence of
fibronectin and HA were detected at molecular level [16], [134], in our model
fibronectin and HA were correctly assembled and deposited in the extracel-
lular space and then detectable by immunotypization (Fig. 3.5 A-F in red).
Furthermore, neo-formed collagen due to its capability to self-assemble in
fibrils and fibers could be detected by on-line SHG signal (Fig. 3.5 G-I in
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gray scale). SHG signal can be used to get information concerning both the
collagen composition as well as its structural modification due to the transi-
tion of fibroblasts from healthy to activated state [125]. In Fig. 3.6 A-C are
reported the quantification of the ECM components: fibronectin (Fig. 3.6
A), HA (Fig. 3.6 B) and collagen (Fig. 3.6 C) in NF-, CAF- and AC-µTP.
Figure 3.6: Quantification of Fibronectin (A) and Hyaluronic Acid (B) ex-
pression (pixels / nuclei) and collagen fraction (C) in NF-µTP (light gray),
CAF-µTP (middle gray) and AC-µTP (dark gray). Whiskers and asterisks
indicate statistical difference with p < 0.05.
Fibronectin and HA were present in higher amount in the CAF- and
AC-µTP than in NF-µTP. This suggests a role of the MCF7-µTP in acti-
vating pathological events at ECM level in the NF-µTP. It is interesting to
point out that we found alterations in the ECM composition just after 24
h of contact between NF-µTP and MCF7-µTP in the microfluidic device.
This indicates that the conditions recreated in our microdevice, induced
both physical contact and biological cross talk between NF-µTP (healthy
zone), and MCF7-µTP (tumor zone). Such ECM-mediated cross talk im-
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plied the ECM reorganization resembling its in vivo pathologic evolution.
In our model the deposition and the up-regulation of HA at extracellular
space are not trivial phenomena due to their relevance in the aggressiveness
of cancers. Indeed, cell proliferation, invasion, metastasis and tumor-stroma
interactions, are mediated by HA level and distribution [16]. Furthermore,
HA levels increased with tumor progression from ductal carcinoma in situ
to later stage invasive carcinoma [135]. Such results on collagenous and
non-collagenous over-expression of ECM macromolecules give further sup-
port that α-SMA and PDGFβ-r positive fibroblasts in the stroma tissue pro-
mote tumor progression [19]. The remodeling of ECM is also correlated with
the up-regulation of MMP-9. Taken together these results indicate that the
microfluidic system reflects some relevant heterologous interactive processes
characterizing the tumor microenvironment.
3.3.4 Time evolution of endogenous collagen network
architecture
A cutting edge strategy used in vivo to study cancer evolution in a non-
destructive manner, is represented by the real time acquisition of the ECM
components by means of multiphoton imaging [63]. How collagen architec-
ture changes during pathologic status is currently used as a clinical biomarker
for tumor diagnosis and staging [59]. For example, SHG and Third Harmonic
Generation (THG) imaging have been used to monitor tumor progression
and carcinogenesis. Information about the interactions between tumor cells,
extracellular matrix and epithelial-stromal communication, as well as the ini-
tiation of collagen remodeling, can be obtained [66]. It is well known that
collagen organization is altered in tumor tissue in comparison to normal one.
We implemented real time SHG imaging in the microfluidic device to mon-
itor the collagen organization during the activation period (from T1 to T2)
of NF-µTP in AC-µTP. In particular, we used two methods to obtain infor-
mation about time evolution of structure, organization and architecture of
collagen fibers: GLCM [136] and CAD [115], [113]. In particular, by using
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GLCM we evaluated the correlation (Cor) in order to detect the transition
of the collagen network from a fine to a wavy, crimped or coarse architec-
ture [137]. The CAD index, instead, gives information about the degree of
assembly of the collagen network [115], [113]. In Fig. 3.7 the behavior of Cor
(Fig. 3.7 A-D) and CAD (Fig. 3.7 E) is reported for NF-µTP, CAF-µTP
and AC-µTP.
Figure 3.7: Correlation curve as a function of distance in µm in NF-µTP
(light gray), CAF-µTP (middle gray) and AC-µTP (dark gray) at time T0
(0 h, A), T1 (24 h, B) and T2 (48 h, C). Correlation length - λ - obtained by
fitting parameters from normalized correlation curves (D) and fold change
of collagen assembly degree - CAD - in NF-µTP (light gray), CAF-µTP
(middle gray) and AC-µTP (dark gray) during culture time (from T0 to T2).
Statistical difference was determined using ANOVA test (p < 0.05).
At time T0 (Fig. 3.7 A) the correlation curve of both healthy tissues
NF-µTP and AC-µTP (T < T1), decayed faster than CAF-µTP one. This
indicates that the collagen assembled by normal fibroblasts had a finer struc-
ture than that of CAF-µTP [137]. As time increased to T1 (Fig. 3.7 B)
the correlation curves of the NF-µTP continued to decay faster than those
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of the CAF-µTP. On the contrary the AC-µTP correlation curve started
to tend toward the CAF-µTP curve. At the end of the culture time (T2,
Fig. 3.7 C), we found that the NF-µTP curve still decreased faster than
Cor of CAF-µTP. Interestingly, the AC-µTP curve completely overlapped
the CAF-µTP curve. The phenomenon of collagen remodeling can be better
pointed out by plotting the value of λ versus culture time. In Fig. 3.7 D
the λ values of the NF-µTP decreased as culture time increased. This rep-
resents the healthy evolution of the tissue: as collagen is synthesized, it is
remodeled by fibroblasts in an even finer structure. On the contrary the λ
of the CAF-µTP remained constant over culture time and its value was al-
ways higher than NF-µTP. This dissimilar trend is a function of the different
ECM remodeling mechanisms of the cells; indeed, depending on tumor type
and stage, fibroblasts assemble the collagen network that is featured by a
coarser structure compared with healthy collagen. The λ of AC-µTP started
to decrease as in the case of NF-µTP from T0 to T1. After T1 (activation
time), the λ of AC-µTP showed an opposite trend and started to increase
reaching a final value close to the value of CAF-µTP. Finally this reflects
the fact that there is a link between epithelial carcinogenesis process and
progressive loss in the fine fibril structure. These results are in accordance
with previous works in which the correlation was applied to human epithelial
tumors [137], [64], [138], [65] and in particular to adenocarcinoma tumors
[66], [136], as in our case. Indeed those studies have demonstrated that
collagen fibers are irregularly distributed without well-defined orientation in
pathological samples, while the morphology of the collagen fibers were highly
arranged in normal samples. This technique is very useful because it allows
discriminating between cancerous and healthy tissue, with clear distinctions
between normal, benign, borderline and malignant tumors. Obviously, the
possibility to use such a technique in vitro is strongly correlated with the
opportunity to produce a living tissue model evolving during culture time
at cellular and extra cellular level. Further investigations on collagen were
performed by CAD analysis (Fig. 3.7 E). In the case of NF-µTP (Fig. 3.7
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E), the CAD increased over culture time, indicating that collagen was con-
tinuously assembled in the stromal chamber. On the contrary, the CAD in
CAF-µTP, remained constant and lower than the NF-µTP for all three time
investigated. This coarsening suggested the presence of less defined fibril or-
ganization compatible with higher value of λ. Finally, the CAD of AC-µTP,
increased in the first time interval (T0-T1) then started to decrease after the
activation time (T1-T2). Taken together such results demonstrated how AC-
µTP moved from healthy to cancer status due to the presence of the MCF7.
We want to point out that the variation of collagen network architecture is
due to several phenomena occurring in the microdevice in the co-culture con-
ditions such as the over-expression of MMPs and the phenotypic activation of
NF into myofibroblasts. These conditions imply that the deposited collagen
network become coarser and less assembled [64]. These results highlight that
our system allows real time recording of the activation of normal stroma at
cellular and extra cellular level very easy way, avoiding time consuming and
destructive procedures.
3.3.5 Correlation between interstitial diffusivity and
ECM evolution
Together with hydraulic conductivity ([139], [140], [141]), diffusivity repre-
sents one of the key factors affecting drug delivery in biological tissues. Their
real time estimation should be of great interest to accurately design both
macromolecule features and therapeutics. By combining multiphoton and
FRAP [117] technique (Fig. 3.8 A) we performed real time measurements of
FITC-Dextran diffusion coefficient in NF-, CAF- and AC-µTP (Fig. 3.8 B).
The possibility to detect SHG from collagen, allowed to perform FRAP
experiments directly in the collagen space (Fig. 3.8 A). Our results show
that the diffusion coefficient of FITC-Dextran was significantly higher in
NF-µTP compared with CAF- and AC-µTP (p < 0.05, Fig. 3.8 B). This
difference can be explained by taking into account the effect of ECM ar-
chitecture and composition on transport properties in tissues [140]. Indeed,
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Figure 3.8: SHG and FRAP techniques to investigate transport properties
in µTP. The ROI (40 µm) was chosen in the collagen space (A). Diffusion
coefficients (B) of FITC-Dextran (3 kDa) in NF-µTP (light gray), CAF-µTP
(middle gray) and AC-µTP (dark gray). Statistical difference was determined
using ANOVA test (p < 0.05).
both non-collagenous components and collagen accumulation in the intersti-
tium depress the diffusion coefficient [142], [143], [144], [145], [146], [147],
[148]. On the contrary, the removal or reorganization of these fibers has been
shown to improve interstitial transport [71]. The ECM composition and the
resultant diffusion coefficient are influenced by tumor-host interactions sug-
gesting that there may be differences between diffusion coefficients measured
in tumors respect to normal tissues. Our findings suggest that the interstitial
transport resistance is strictly related to the organization, architecture and
composition of the ECM. Indeed when we move from the healthy stroma
(NF-µTP) to pathologic stroma (CAF-µTP) we observed: (i) the increase of
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HA, fibronectin and collagen fraction (Fig. 4.6); (ii) the transition from a
fine to a coarse arrangement of the collagen network (Fig. 3.7). Such condi-
tions induced both ”interstitium crowding” and reduction of the ECM mesh
size that ultimately lead to an increase of frictional interaction between dex-
tran and ECM. Interestingly, the AC-µTP behaved as CAF-µTP in terms of
diffusion coefficient (Fig. 3.8 B). This indicates that our system is able to
detect the stromal activation also in terms of transport properties.
3.4 Conclusions
In this work a new microfluidic platform was presented as a tool for study-
ing the impact of reciprocal interactions between fibroblasts and tumor cells
through the integration of 3D engineered tissue model. The optical acces-
sibility of the microdevice coupled with the high-fidelity features of our 3D
tissue model allowed, for the first time, to monitor and to quantify in real
time healthy / tumor transition in vitro at ECM level. Since to date such
information can be obtained only by means of in vivo experiments [61], we
argue that our system paves the way for a new class of drug screening plat-
form that include, as design criterion, the interaction between therapeutics
and tumor stroma. Moreover the versatility of our model could allow the
incorporation of tumor vascular component by the introduction of endothe-
lial cells in lateral channels or the perfusion of new therapeutic targets into
lateral channels emulating the in vivo intravenous injections. On the basis of
these observations we believe that our system (microdevice and 3D-µTP) can
bridge the gap between current 3D tissue model and animal models reducing
expensive and time-consuming protocol nowadays used in preclinical studies.
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Chapter 4
Comparison of the behavior of
tumor breast spheroids and
microtissues in response to
free-Doxorubicin treatment
4.1 Introduction
Traditionally, preclinical studies for anti-cancer drug testing are usually per-
formed in two dimensional (2D) in vitro culture [149]. In 2D systems, cells
are deprived of the extracellular matrix that is fundamental in regulating tu-
mor progression [150]. As consequence of the lack in cell-matrix interactions,
these simplified systems do not faithfully recapitulate the complexity of the
tumor microenviroment in vivo and consequently drug response is controver-
sial [118]. On the other hand, animal testing in clinical research should be
limited since their use is time-consuming, also expensive and poor predictive
of human response to drug [151].
The 3D cell culture approaches have dramatically improved our under-
standing of the role of tumor microenvironment incorporating the extracel-
lular matrix (ECM), stromal cells and physical signals [150]. Spheroid is one
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of the most studied and established cancer models since it recapitulates the
architecture of the tumor core in vivo. Several studies have demonstrated
the simplicity and high reproducibility of this model, making it suitable as a
anti-cancer drug screening platform. However spheroids present some limi-
tations since they are compact cell aggregates that do not interact with their
extracellular milieu and do not have physical resistance provided by the ECM
[152], [153], [154]. Concerning drug testing, it is already known that tumor
ECM plays a key role in triggering mechanisms related to chemoresistance
and act as barrier in drug diffusion. Although the ECM is important to
regulate this feature, only few works reported the incorporation of stromal
cells in spheroid models, underlining the limitation of these models [87]. By
this way, there is an increasing need of a more relevant tumor model reca-
pitulating various aspects of cancer including three-dimensional architecture,
multiple cell types and an extracellular matrix barrier [87]. With the advance
in tissue engineering, microcarriers based approach have been employed to
guide cell development into 3D organization to better mimic the native tissue,
providing a more reliable tool for drug testing. Unlike what happens in cel-
lular spheroids, in the case of cell-seeded microcarriers, the cells are induced
to grow on the microcarrier surface and under controlled culture condition
are able to synthesize endogenous ECM. The microcarriers based approach
can lead to a more realistic tumor tissue model for in vitro applications such
as drug screening.
In the present study, we developed an in vitro 3D breast cancer micro-
tissue and spheroid model using MCF-7 cell line in monoculture and cocul-
ture with cancer-associated fibroblasts (CAF). The 3D microtissue model is
obtained by seeding tumor and/or fibroblast cells on porous biodegradable
microcarriers in a dynamic culture system according to previous works [6],
[51]. Anticancer effects of Doxorubicin (DOX), one of the most widely used
chemotherapeutic agent [155], were studied and IC50 values were compared
between microtissues and spheroids 3D culture model. Moreover drug diffu-
sion in the different model was studied by means of FRAP method. Finally,
106
we found that breast cancer cells in the 3D model present a different behavior
in terms of chemoresistance when they are cultivated in different 3D models
in monoculture and coculture. Moreover when they are in coculture with
CAF, they resembled some features of xenograft tumor model, bring near
this model to the in vivo condition. Therefore, tumor microtissues could be
valuable candidates for drug screening assay.
4.2 Materials and Methods
4.2.1 Cell type
Human breast adenocarcinoma cells (MCF7) and cancer associated fibrob-
lasts (CAF), (kindly donated by Daidone and Kojima’s group, respectively)
were sub-cultured onto 150 mm Petri dishes in RPMI-1640 (Roswell Park
Memorial Institute) and Dulbecco’s Modified Eagle Medium respectively,
with high glucose, containing 10% fetal bovine serum, 100 µg/ml L-glutamine,
100 U/ml penicillin/ streptomycin. Cells were maintained at 37◦C in humid-
ified atmosphere containing 5% CO2. CAF were stable transfected with
pLVX-DsRed-express2-N1 (ˆIex 554nm, λem 591nm) viral vector (Clontech,
USA).
4.2.2 Microbeads production
Gelatin porous microbeads (GPMs) have been prepared by following a pre-
viously established protocol [6]. GPMs have been stabilized by crosslink
reaction with GPMs glyceraldehydes (GAL), in order to make them stable
in aqueous environment at 37 ◦C, as previously described [6]. GAL at 5%
w/w of the microbeads has been used to perform all the experiments.
4.2.3 Dynamic cell seeding
Before using, dry GPM were sterilized in absolute ethanol 24 h on a rotating
plate. Then, GPMs were washed twice in sterile phosphate-buffered saline
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(PBS) without calcium and magnesium solution. Finally, before cell seeding,
PBS was replaced by fresh culture medium. For homotypic culture (MCF7
alone) 50mg of GPMs were loaded together with 7.5*105 cells (30 cell/GMP
ratio). To help cell seeding on GMPs an intermittent stirring regime (30
min at 0 rpm, 5 min at 30 rpm) for 6 h has been performed. Then, dynamic
cultures were kept under continuous stirring at 30 rpm for up to 12 days. For
heterotypic culture (CAF/MCF7-µTP) at day 6th, MCF7 cells were added
in a ratio 1:3 to CAF cells into spinner flask. Medium was changed on the
first day and every 3 days until the end of the experiments. For fibroblasts,
from the day 2nd, 50 µg/ml of ascorbic acid were added.
4.2.4 Homotypic and heterotypic spheroid formation
MCF-7 cells were trypsin-treated and counted. Subsequently, they were
seeded onto round bottom non-tissue culture treated 96 well-plates (Falcon,
BD NJ, USA) at a concentration of 2500 cell/well in RPMI 10% FCS supple-
mented with 20% methylcellulose stock solution. For cocultured spheroids
we used a total of 2500 cell/well, where CAF were seeded in a ratio 3:1 with
MCF7 cells. For preparation of methylcellulose stock solution we autoclaved
3 grams of methylcellulose powder (M0512, Sigma-Aldrich) in a 250 ml bottle
containing a magnetic stirrer. The autoclaved methylcellulose was dissolved
in preheated 125 ml basal medium (60◦C) for 20 min (using the magnetic
stirrer). Thereafter, 125 ml medium (RT) containing double amount of FCS
(20%) was added to a final volume of 250 ml and the whole solution mixed
overnight at 4◦C. The final stock solution was aliquoted and cleared by cen-
trifugation (5000 g, 2 h, RT). Only the clear highly viscous supernatant
was used for the spheroid assay (about 90-95% of the stock solution). For
spheroid generation was used 0.24% methylcellulose. Spheroids were grown
under standard culture conditions (5% CO2, at 37
◦C) and harvested at dif-
ferent time points for further investigations.
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4.2.5 Drug treatment and cytotoxicity
About 10 µL of MCF7-µTP solution and one CAF/MCF7-µTP were trans-
ferred into well of a round bottom 96 well plates in order to have the same cell
density. Both spheroids and µTP were treated with free doxorubicin (Sigma)
at 4, 8 and 16 µg/ml after dilution from a stock solution (40 µg/ml). One
row of 96-wells plate was used as control with 200 µL culture medium only.
After incubation for 48 and 72 h at 37◦C in humidified atmosphere contain-
ing 5% CO2, 20 µL of 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium
bromide (MTT) solution (5 mg/ml) was added to each well, and the plate
was incubated for another 4 h, allowing the viable cells to reduce the yellow
MTT into dark-blue formazan crystals, which were dissolved into 100 µL
of dimethyl sulfoxide (DMSO). The absorbance of individual well was mea-
sured at 470 nm by a microplate reader (Enspire Multimode Plate Reader
PerkinElmer). All experiments were done in triplicates.
4.2.6 Doxorubicin penetration imaging
µTP and spheroids treated with doxorubicin (DOX) were washed three times
with PBS and fixed in 4% paraformaldehyde (PFA) in PBS for 20 min.
Cell nuclei were stained with 1 µg/ml 4’,6-diamidino-2-phenylindole (DAPI,
Sigma-Aldrich). DOX fluorescence was observed under a confocal microscope
(Leica) with excitation at 488 nm and with a 40X water objective (NA =
1.10). For drug penetration study, µTP and spheroids treated with 8 µg/ml
of DOX were aquired with a magnification 3.5.
4.2.7 Doxorubicin penetration quantification
All the images were analyzed using ImageJ software. First, the images were
converted to grey scale. An adaptive thresholding method was applied to
separate the foreground from background. Multiple images were quantified
and averaged. To determine drug penetration, we detected the boundary of
the region of interest (ROI). Signal intensity per ROI was quantified as image
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fluorescent intensity by a specific area in the image [152]. Pixels’ fluorescence
intensity of regions of interest were counted and normalized by the area.
4.2.8 Diffusion measurement by fluorescence recovery
after photobleaching (FRAP)
Diffusion of DOX was measured with fluorescein isothiocyanate with simi-
lar molecular weight (389.38 g/mol, Sigma) by Fluorescence Recovery After
Photobleaching (FRAP) technique. FRAP measurements were conducted
with a laser scanning microscope (TCS SP5, Leica). Samples were illumi-
nated with a 25X (NA = 0.95) objective and 488 nm excitation line from
Argon laser operating with 5% output power. The bleaching time was 5.16
s and the total ROI fluorescence images after photobleaching were collected
at intervals of 0.263 s at 512 x 512 pixel resolution using a pinhole of 600
µm, zoom factor 2.5 (with a zoom-in during bleaching) and 1000 Hz. Diffu-
sion coefficients were calculated from FRAP experiments. Briefly, the mean
fluorescence in the bleached region over time was converted to normalized
fractional fluorescence intensity [118]:
f =
Ft − F0
F∞ − F0 (4.1)
where Ft is the fluorescence intensity at time t, F0 is the fluorescence
intensity immediately after bleaching, and F∞ is the fluorescence after com-
plete recovery. The normalized fractional fluorescence intensity was plotted
versus time and fitted with an exponential curve. The equation of curve was
used to determine the half-recovery time (τ) at f = 0.5. Finally, the diffusion
coefficient can be calculated as follow:
D =
ω2
4t
(4.2)
where ω is the initial spot radius (40 µm).
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4.2.9 Immunofluorescence staining, imaging and quan-
tification
For immunofluorescence staining, formalin-fixed and paraffin embedded µTP
and spheroids were unmasked by heat antigen retrieval protocol by citrate
buffer; washed with PBS containing 0.2% Triton X-100, blocked with FBS
and 5% BSA solution and incubated with primary antibody (E-cadherin
1:250, Claudin-1 1:250, ZO-1 1:50). All the antibodies were purchased by
Abcam (UK). Secondary antibody incubation and DAPI staining were per-
formed, before closing the slices with glycerol solution. The same immunoflu-
orescence staining was made in mouse xenograft model. The fluorescent im-
ages, previously acquired by using a multichanneled Leica TCS SP5 II, were
analyzed for semi-quantitative evaluation with ImageJ. After threshold, the
amount of signal was divided by the total number of cells (previously ob-
tained by counting their nuclei) in each image [114].
4.2.10 Statistical analysis
Differences between two or more groups were evaluated (pvalue < 0.05) us-
ing one-way analysis of variance (ANOVA). A Gaussian distribution for each
population was assumed. For pair-wise comparisons within each experimen-
tal group, Tukey’s post test was used.
4.3 Results
In this work two types of 3D cancer models were compared: spheroid and
µTP in homotypic (MCF7) and heterotypic (CAF/MCF7) condition. DOX
response was investigated in µTP models in terms of cytotoxicity, imaging,
drug diffusion and penetration and compared to a classic model used in cancer
research, the spheroid model.
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4.3.1 In vitro imaging and cytotoxicity assay
Both homotypic and heterotypic spheroids and µTP were exposed to DOX
for 48 and 72 h and then cell viability was assessed by MTT assay. From this
colorimetric proliferation assay it is possible to know the number of viable
cells by measuring the quantity of formazan produced at 470 nm. Fig. 4.1
shows the cell survival of MCF7 spheroids and µTP as a function of DOX
concentration (4-8-16 µg/ml) for 48 (Fig. 4.1 A) and 72 h (Fig. 4.1 B). In
both homotypic models, higher is the DOX concentration lower is the percent
of cell proliferation. As we can see, it was necessary an incubation time of
72 h in order to have a reduction of 50% of cell population for both models.
In particular, the IC50 (concentration for 50% cell death) of DOX for MCF7
spheroids and µTP was calculated to be 8 µg/ml and 4 µg/ml, respectively.
Figure 4.1: Cytotoxicity assay in MCF7 spheroids (light gray) and µTP
(middle gray) after treatment with DOX at 4, 8 and 16 µg/ml for 48 (A) and
72 h (B).
In Fig. 4.2 we reported optical (Fig. 4.2 A-D and I-N) and fluorescence
(Fig. 4.2 E-H and O-R) images of heterotypic spheroids and µTP after DOX
treatment for 48 and 72 h. From spheroids brightfield images (Fig. 4.2
A-D), the effect of DOX is strictly limited to the outer cell layers (death
cells detached from the spheroid configuration) but the spheroid diameter
remained roughly the same. On the other hand, the size of heterotypic µTP
treated with DOX (Fig. 4.2 I-N) was reduced with the extending of exposure
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time and the increase of drug concentration. The effect was prominent when
treated with DOX at concentration of 16 µg/ml for 72 h. It is well known that
reduction in tumor size represents one of the positive effects of an anticancer
drug [151].
Figure 4.2: Brightfield images of CAF/MCF7 spheroids (A-D) and µTP
(I-N) after 72 h of DOX treatment at 4, 8 and 16 µg/ml (A, I controls).
Fluorescence distribution of DOX within CAF/MCF7 spheroids (E-H) and
µTP (O-R) upon 72 h incubation with DOX at 4, 8 and 16 µg/ml (E, O
controls); Cytotoxicity assay in CAF/MCF7 spheroids (light gray) and µTP
(middle gray) after treatment with DOX at 4, 8 and 16 µg/ml for 48 (S) and
72 h (T).
Furthermore, the penetration of DOX, which fluoresces in green, was as-
sessed with confocal microscopy. For visualization, cells were stained with
DAPI (blue signal). From confocal images (Fig. 4.2 E-H and O-R), is ob-
served an apparent time-dependent DOX penetration for both models. After
72 h of treatment, DOX penetrated into the nuclei of 3D cultured cells in
a dose-dependent manner. Especially, DOX displayed a homogeneous and
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dose-dependent accumulation region of µTP. After 72 h, DOX penetration is
higher in µTP (Fig. 4.2 O- R) than spheroids (Fig. 4.2 F-H) suggesting that
µTP structure is less compact than spheroids and thus more readily allows
the penetration of drugs at very high concentrations. Furthermore, SHG
signal (Fig. 4.2 O-R, in gray scale) was detected only in µTP configuration,
indicating the presence of collagen fibers produced and synthesized by fibrob-
lasts. SHG images showed a random distribution of fiber orientations and a
wide inter-fiber spacing in tumors. MTT cytotoxicity results shown in Fig.
4.2 S and T, reveals that there is no inhibition effect in cell proliferation after
the treatment of CAF/MCF7 spheroids with DOX both 48 and 72 h. On the
contrary, the reduction of 50% of cell population in CAF/MCF7 µTP is ob-
served at 8 µg/ml of doxorubicin exposure for 72 h. However, the inhibition
of cell viability for CAF/MCF7 µTP was lower than that for the homotypic
µTP counterparts. Definitely, MTT results demonstrated that heterotypic
cultures with stromal fibroblasts exhibit significantly higher drug resistance
that homotypic cultures both in spheroid and µTP model.
4.3.2 µTP and spheroid penetration study
It is well known that the accumulation and penetration of anti-cancer drugs
in tumors are essentially to achieve effective chemotherapy responses in can-
cer therapy. For this reason, the penetration and diffusion of DOX were
examined. Penetration was evaluated by analyzing images of DOX fluores-
cence acquired with magnification 3.5 in order to have a better visualization
of DOX intercalation into cell nuclei. For analysis, we chose the intermediate
concentration of 8 µg/ml that correspond to the IC50 value determined for
CAF/MCF7-µTP.
Fig. 4.3 A-B show representative CAF/MCF7 spheroid (Fig. 4.3 A)
and microtissue (Fig. 4.3 B) images with 3.5 magnification while Fig. 4.3
C shows quantification of mean fluorescence in both 3D models normalized
by area. From quantification analysis, homotypic and heterotypic spheroids
showed limited penetration when exposed to 8 µg/ml of free DOX. On the
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Figure 4.3: Fluorescence images of DOX within CAF/MCF7 spheroids (A)
and µTP (B) with magnification 3.4 upon 72 h incubation with DOX at 8
µg/ml; Doxorubicin distribution in CAF/MCF7 spheroids (light gray) and
µTP (middle gray) per area after treatment with DOX at 8 µg/ml for 72 h
(C); Diffusion coefficients (D) of Fluorescein in CAF/MCF7 spheroids (light
gray) and µTP (middle gray). Statistical difference was determined using
ANOVA test (p < 0.05).
other hand, DOX efficiently penetrated in µTP models, both in homotypic
and heterotypic configurations respect to the spheroid counterparts (p <
0.05). Furthermore, DOX penetration is lower in CAF/MCF7-µTP respect
to MCF7-µTP, because of presence of endogenous ECM. In order to better
understand the difference in doxorubicin transport in two models, we have
focused on diffusion mechanism through the interstitial space of spheroids
and µTP. We measured the diffusion coefficient of fluorescein in homotypic
(MCF7) and heterotypic (CAF/MCF7) spheroids and µTP using FRAP,
which measures the fluorescent intensity recovery in the bleached region over
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time (Fig. 4.3 D). The measured diffusivity within µTP was 3.95 ± 0.704
E-07 cm2/s and 2.10 ± 0.543 E-07 cm2/s for MCF7 and CAF/MCF7 µTP,
respectively. In spheroid model, the diffusion coefficient is equal to 1.98 ±
0.483 E-07 cm2/s for MCF7 and 1.27 ± 0.456 E-07 cm2/s for CAF/MCF7
culture. In both cases, the diffusion coefficient decreased with the complex-
ity of the system from homotypic to heterotypic culture but increased in
µTP configuration respect to spheroid model, at the same cell culture. Defi-
nitely, spheroids showed limited diffusion of molecular probe as well as DOX
distribution compared to µTP.
4.3.3 Expression of cell adhesion molecules in µTP and
spheroid models
Since adhesion molecules play vital roles in cell morphology and function,
we also investigated whether the expression of adhesion molecules differed
in homotypic (Fig. 4.4 A-B) and heterotypic (Fig. 4.4 C-D) condition in
spheroids and µTP.
Since in most solid tumors derived from epithelial tissues, nests of ma-
lignant tumor cells are linked through junction proteins such as E-cadherin,
claudins and ZO-1 [156], we decided to analyze these three markers by im-
munofluorescence staining in spheroids and µTP and compared with xenograft
models in which MCF7 cells were injected subcutaneously.
Fig. 4.4 A-E show fluorescence images of cell adhesion markers E-cadherin
(in red) in homotypic and heterotypic spheroids and µTP, respectively. To
better assess the level of expression of intercellular junction, quantification
of the staining pattern was carried out using image analysis (Fig. 4.4 F).
From quantification analysis we found a higher expression level in the case of
spheroids, both homotypic (Fig. 4.4 A) and heterotypic (Fig. 4.4 C) respect
to µTP counterparts (Fig. 4.4 B and D) and xenograft model (Fig. 4.4 E) (p
< 0.05). The same trend was found for Claudin-1 (Fig. 4.5 A-E) and ZO-1
(Fig. 4.6 A-E) expressions in spheroids and µTP. In particular, the level of
ZO-1 expression is equal between MCF7 spheroids and µTP (Fig. 4.6 F)
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Figure 4.4: E-cadherin fluorescence images (red signal) in MCF7 spheroids
(A) and µTP (B), in CAF/MCF7 spheroids (C) and µTP (D) and in
xenograft mouse model (E); Quantification of E-cadherin (F) expression (pix-
els / nuclei) in MCF7 spheroids and µTP, in CAF/MCF7 spheroids and µTP
and in xenograft mouse model. Statistical difference was determined using
ANOVA test (p < 0.05).
(p > 0.05) but it was shown the loss of this tight junctions when MCF7
were cultured with CAF in heterotypic µTP. These results showed that the
expression of adhesion and tight molecules in µTP model was more similar
to that of tumors grown in vivo than those of spheroid-cultured cells.
4.4 Discussions
In this study, we have compared a 3D homotypic and heterotypic tumor µTP
model to the respective spheroid models, in order to assess the difference in
terms of chemoresistance between the two models in response to DOX treat-
ment. It is well known that tumor in vivo are not merely an aggregation
of cancer cells but are composed with other cells of microenvironment that
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Figure 4.5: Claudin-1 fluorescence images (red signal) in MCF7 spheroids (A)
and µTP (B), in CAF/MCF7 spheroids (C) and µTP (D) and in xenograft
mouse model (E); Quantification of Claudin-1 (F) expression (pixels / nuclei)
in MCF7 spheroids and µTP, in CAF/MCF7 spheroids and µTP and in
xenograft mouse model. Statistical difference was determined using ANOVA
test (p < 0.05).
contribute to drug resistance. Therefore it is important to incorporate this
complex structure in models used to study novel cancer therapies. The effect
of one of the most commonly used anti-cancer drug, DOX, on MCF7-µTP
and CAF/MCF7-µTP was evaluated by cytotoxicity assay, imaging, drug
penetration and diffusion studies. The same issues were also investigated on
spheroid model, both homotypic and heterotypic. The results of this work
demonstrate that CAF/MCF7-µTP are able to better recapitulate the in
vivo tumor microenvironment, in which cells, in the right context, are em-
bedded in their endogenous ECM, countinously synthesized and remodeled
by neighbors fibroblasts cells. In contrast, tumor spheroid that is a multi-
cellular aggregate lacks a controlled microarchitecture and significant ECM
re-organization and therefore drug response is distorted. In our model, the
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Figure 4.6: ZO-1 fluorescence images (red signal) in MCF7 spheroids (A) and
µTP (B), in CAF/MCF7 spheroids (C) and µTP (D) and in xenograft mouse
model (E); Quantification of ZO-1 (F) expression (pixels / nuclei) in MCF7
spheroids and µTP, in CAF/MCF7 spheroids and µTP and in xenograft
mouse model. Statistical difference was determined using ANOVA test (p <
0.05).
presence of the microcarriers allows collagen synthesis and sustains its as-
sembly reproducing the tumor architecture found in vivo [44]. Co-culturing
cancer cells with fibroblasts in 3D heterotypic µTP can mimic breast can-
cer heterogeneity, allowing a more physiological response to screening. In
both models, the supplementation of fibroblasts into 3D culture not only
elicits physico-chemical changes of cancer cells and microenvironment, but
also brings about differences in drug response compared to single culture of
cancer cells [157].
Furthermore MCF7 spheroid model exhibits higher drug resistance re-
spect to µTP configuration. The possible reasons can be conferred to the
spheroid ability to block the diffusion of the drug to the outer layers in
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which cells are more proliferative and therefore more sensible to DOX treat-
ment. Indeed, the oxygen gradient within the spheroid provides a hypoxic
core consisting of cells more resistant to drug. Consequently a greater drug
resistance is showed when MCF7 spheroids are treated with DOX respect to
MCF7-µTP. In both cases, the models were limited because of the lack of
stromal component and therefore they cannot be used as drug screening plat-
form. When we cultured MCF7 with CAF, drug mass transfer was expected
to be much more limited respect to monoculture due to stromal barrier. Re-
cently, a work has demonstrated that heterospheroid conditions with stromal
fibroblasts exhibit enhanced resistance to drug over homospheroids [87]. In
our study, the co-culture CAF/MCF7 exhibited a significant different sensi-
tivity to DOX when were included both in spheroid or µTP configuration.
In particular, drug concentration in CAF/MCF7 spheroids increased over
time but it was not sufficient to achieve the IC50 value. On the contrary,
CAF/MCF7-µTP halved their viability after DOX treatment with a con-
centration of 8 µg/ml. The different behavior can be attributed to different
morphology of models. We also hypothesized that the rapid drug penetra-
tion in µTP might be possible due to the greater intercellular space between
cells. Therefore, it may be argued that the aforementioned findings are at-
tributable to a diminished drug diffusion rate in spheroids as demonstrated
by FRAP experiments. Previous studies using fluorescent drugs or macro-
molecules have been shown poor penetration of DOX into deeper layers of
spheroids [158]. These data strongly confirmed the results obtained in our
work in terms of drug penetration in spheroid model. The difference of the
cellular distribution of DOX in spheroids and µTP suggested that there are
different physical barriers that hinder the diffusion of drugs. The ECM is
known to be a physical transport barrier of molecules through tissue. It
is composed of fibrous structural proteins (collagen and elastin), adhesive
proteins (fibronectin and laminin) and proteoglycans (hyaluronic acid) [156].
Among them, collagen content was a significatively determinant of the dif-
fusive transport of drugs in solid tumors [142]. In our work, we demostrated
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the presence of well organized collagen fibers in CAF/MCF7-µTP, but not
in CAF/MCF7 spheroids. Furthermore the high porosity and interconnected
porous structure in microscaffold lead to quick diffusion of molecules in a liq-
uid environment, which could favor mass transfer for cell aggregates within
scaffolds [118]. Although matrix components could be considered a barrier to
drug transport, the rapid turnover of ECM on one side and the high porosity
and interconnected structure in µTP model on the other side, allowed more
drugs to infiltrate more freely inside the matrix structure, increasing DOX
anti-cancer activity. These two important aspects enable to have efficient
molecular diffusion of drug within the scaffolds present in µTP configura-
tion, similar to small molecular diffusion in the tumor microenvironment in
vivo [118].
One of the key features of epithelial tumors is the presence of intercellular
junctions, which link cells to one another, and act as barriers to the penetra-
tion of molecules with a molecular weight greater than 400 Da, as DOX. Sev-
eral studies have shown that upregulation of epithelial junction proteins was
correlated with increased resistance to therapy, including chemotherapeutics
[156]. In the last few years, it has become increasingly apparent that cell
death, especially apoptosis, strongly depend on cell adhesion [159]. Previous
studies using multicellular layer models have shown poor drug distribution
into tumors with high packing density [158]. In our case, impaired penetra-
tion of anticancer agents through spheroids, both homotypic and heterotypic,
derived from cells with tightly packed cells in comparison with loose packing
cells in µTP model. Since adhesive properties of cells contribute to resis-
tance to DOX treatment, in this work we further examined one of the most
important adhesion junctions, the E-cadherin, in both models. E-cadherin
is thought to function as a tumor suppressor in numerous tissues and has
been shown to be a useful prognostic indicator for some tumors, illustrating
the importance of cell-to-cell adhesion proteins in cancer progression [160].
As reported in recent papers, the presence of strong cell-cell adhesion medi-
ated by E-cadherin prevent cell apoptosis and therefore promote cell survival
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[159]. In this way, when CAF/MCF7 spheroids were exposed to DOX treat-
ment, were more resistant to drug due to high cell-cell adhesions. On the
contrary, in CAF/MCF7-µTP exhibited lower expression of epithelial cell
adhesion markers E-cadherin. The expression of E-cadherin in CAF/MCF7-
µTP was quite similar to what found in a xenograft murine model. Moreover,
changes in tight junctions have been shown to be an early and key aspect
in cancer metastasis [161]. One of the important role of tight junctions is
the permeability barrier function that regulates the passage of water, ions
and various macromolecules through paracellular spaces [162]. Of the pro-
teins comprising tight junctions, integrate membrane proteins claudin-1 and
ZO-1 have been investigated. A previous study reported a significant loss
of claudin-1 protein in breast cancer cells, suggesting that this protein may
play a role in invasion and metastasis [161]. Tokes et al. (2005), have demon-
strated a significant loss of claudin-1 protein in breast cancer cells in sections
from surgically resected breast specimens by immunostaining [161]. In our
work, we reported a loss of claudin-1 and ZO-1 proteins in CAF/MCF7-µTP,
showing a quite similar situation in xenograft model. These results are in
accordance with previous works in human tumors where levels of ZO-1 were
significantly lower in patients with metastatic disease compared with those
remaining disease-free [163]. Moreover, these reports of decreased tight junc-
tion protein expression in CAF/MCF7 µTP are consistent with the gener-
ally accepted idea that tumorigenesis is accompanied by a disruption of tight
junctions, a process that may play an important role in the loss of cohesion,
invasiveness and lack of differentiation observed in cancer cells [164].
Taken together, comparisons of drug responsiveness of our µTP system
with the standard spheroid model indicate that tumors grown in the micro-
carriers may be more appropriate model to study certain aspects of cancer
progression [32]. In particular, the microscaffold provides good spatial inter-
connectivity between cells, a high surface-to-volume ratio and good poros-
ity for fluid transport. Furthermore, it is also able to mimic the physical
interaction of the tumor cells with the microenviroment defined by synthe-
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sis of endogenous collagen directly by stromal cells. These results made
CAF/MCF7-µTP a more valuable tool for highly predictive drug testing in
vitro, in comparison to the spheroid model where the cells, being densely
packed each other, did not recapitulate the tumor microenvironment in vivo.
4.5 Conclusions
In this study, we report a new three-dimensional in vitro model that can be
used for the investigation of drug response against breast cancer cells. Our
system has presented several advantages respect to the classical spheroid
model: the biodegradable microscaffolds have a good porosity that provide
the spatial interconnectivity between cells and affect the synthesis of endoge-
nous ECM directly by stromal cells. Moreover together with the presence
of the ECM, tumor cells have lower expression of adhesion molecules, typ-
ical aspect observed during tumorigenesis. Because the morphology of our
system is closer to xenograft model respect to the spheroid model observed,
it suggests that the µTP system may be a useful in vitro screening tool for
testing innovative approaches of drug delivery such as nanoparticles sensi-
ble to specific characteristic of tumor microenvironment (acidic pH, altered
redox potential or up-regulation of specific proteins) [165].
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Chapter 5
Delivery of MMP2-responsive
Nanoparticles in healthy and
tumor microtissues
5.1 Introduction
Conventional cancer chemotherapeutic drugs often fail to kill cancer because
their efficacy is altered by nonspecific cell and tissue biodistribution, lead-
ing severe adverse effects on normal tissues [166], [167]. This aspect de-
rives from undesirable properties of drugs, such as poor water solubility,
low tumor targeting and insufficient cellular drug uptake [168]. Given the
progress in material science and pharmaceutics, several typologies of thera-
peutic nanoparticles have been developed with diverse sizes, architectures and
surface properties [167]. These include liposomes, polymeric nanoparticles,
micelles, mesoporous silica nanoparticles, dendrimers, carbon nanotubes and
inorganic nanoparticles [169]. The clinically significant impact of nanoparti-
cles, regardless of their type, is the improvement of drug efficacy, increasing
tumor tissue selectively and minimizing side effects [170]. Indeed, this is
achievable by their capacity to increase local drug concentration by carrying
the drug to the specific target site [169]. After systemic (intravenous) admin-
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istration, drug must first extravasates from the blood system, passes through
the ECM (extracellular matrix), binds to cells and then crosses the surface
membrane to enter into target cells [166]. During this path, nanoparticles en-
counter several physiologic barriers such as heterogeneous tumor perfusion,
irregular blood flow, high cell density, acidic pH and increased interstitial
pressure [171]. In this context, stimuli-responsive nanoparticles are able to
achieve controlled drug delivery by exploiting the pathophysiologic charac-
teristic of tumor microenvironment, like lowered interstitial pH or increased
levels of enzymes [172]. For example, metalloproteinases (MMPs) are over
expressed in a variety of malignant tumors and play a critical role in tumor
invasion and progression [173]. Therefore they can be used as a biochem-
ical trigger for drug release during cancer therapy since the inhibition of
their proteolytic activity by using tissue inhibitors of the metalloproteinases
(TIMPs) was failed [174], [175]. Among MMPs family, MMP-2 (also known
as gelatinase A) hydrolyze type IV collagen, degrading ECM matrix and
play an important role in metastasis of breast, lung, colorectal and ovarian
tumors [176]. In a recent work, Guarnieri et al. (2014), proposed the use of
a novel nanocarrier able to carry safely doxorubicin in tumor tissues and to
respond to MMP-2 enzyme [176]. The nanocarrier is composed by a spherical
polystyrene nanoparticle covalently bonded with a Tumor-Activated Prodrug
(TAP) composed by polyethylene glycol (PEG), a peptide sequence sensitive
to MMP-2 and doxorubicin. The presence of the MMP-2 enzyme in situ,
leads to the disruption of the bond between the peptide and the doxorubicin,
with the consequent diffusion of the drug. The same technology was used
by this group to fabricate biodegradable systems based on a FDA-approved
material, polyethylene glycol (PEG) [165]. This new system is composed by
biodegradable poly(d,l-lactic-co-glycolic acid) (PLGA) - block - polyethylene
glycol (PEG) copolymer (namely PELGA), blended with TAP composed of
a MMP2-sensitive peptide bound to doxorubicin (DOX) at the C- terminus
and to PLGA molecule at the N-terminus [165]. In the present work we tested
this MMP-2-stimuli-responsive nanoparticles in terms of DOX release normal
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and tumoral 3D heterotypic microtissues (µTP). Indeed, normal µTP were
fabricated seeding normal fibroblasts (NF) and epithelial breast cell lines
(MCF10) as well as tumoral µTP containing epithelial breast cancer cells
(MCF7) and cancer-associated fibroblasts (CAF). It is well recognized that
tumor stroma physically limits the penetration of molecular drugs as well as
nanotherapeutics into the tumors [166]. Nanoparticle cytotoxicity was tested
in heterotypic normal and tumoral µTP to demonstrate their significant se-
lectively. We believe that the use of 3D microtissue model as a nanoparticle
delivery platform is able to forecast a more realistic therapy response near
to in vivo conditions.
5.2 Materials and Methods
5.2.1 Cell type
Normal mammary fibroblasts (NF) and cancer associated fibroblasts (CAF),
kindly donated by Kojima’s group, were sub-cultured onto 150 mm Petri
dishes in DMEM (Dulbecco’s Modified Eagle Medium) with high glucose,
containing 10% fetal bovine serum, 100 µg/ml L-glutamine, 100 U/ml peni-
cillin / streptomycin. Human non tumorigenic epithelial cell lines (MCF10)
from ATCC and human breast adenocarcinoma cells (MCF7) kindly donated
by Daidone’s group were sub-cultured onto 150 mm Petri dishes in MEBM
(Modified Eosin Methylene Blue Agar for medium) and RPMI-1640 (Roswell
Park Memorial Institute) respectively, with high glucose, containing 10% fe-
tal bovine serum, 100 µg/ml L-glutamine, 100 U/ml penicillin / strepto-
mycin. Cells were maintained at 37 ◦C in humidified atmosphere containing
5% CO2. Fibroblasts were stable transfected with pLVX-DsRed-express2-N1
(λex 554nm, λem 591nm) viral vector (Clontech, USA).
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5.2.2 Microbeads production
Gelatin porous microbeads (GPMs) have been prepared by following a pre-
viously established protocol [6]. GPMs have been stabilized by crosslink
reaction with GPMs glyceraldehydes (GAL), in order to make them stable
in aqueous environment at 37 ◦C, as previously described [6]. GAL at 5%
w/w of the microbeads has been used to perform all the experiments.
5.2.3 Dynamic cell seeding
Before using, dry GPMs were sterilized in absolute ethanol 24 h on a ro-
tating plate. Then, GPMs were washed twice in sterile phosphate-buffered
saline (PBS) without calcium and magnesium solution. Finally, before cell
seeding, PBS was replaced by fresh culture medium. For heterotypic culture
(NF/MCF10- and CAF/MCF7-µTP) 50 mg of GPMs were loaded together
with 7.5*105 of fibroblasts (30 cell/GMP ratio). To help cell seeding on
GMPs an intermittent stirring regime (30 min at 0 rpm, 5 min at 30 rpm)
for 6 h has been performed. Then, dynamic cultures were kept under con-
tinuous stirring at 30 rpm for up to 12 days. At day 6th, MCF10 and MCF7
cells were added in a ratio 1:3 to NF and CAF cells into spinner flask, respec-
tively. Medium was changed on the first day and every 3 days until the end
of the experiments. For fibroblasts, from the day 2nd, 50 µg/ml of ascorbic
acid were added.
5.2.4 Cell growth
At the day 1, 6, 7 and 12 of culture, 1 ml aliquot of NF/MCF10- (healthy
tissue) and CAF/MCF7-µTP (tumor tissue) were collected from the spinner
flask for cell growth monitoring on the GPMs. It’s necessary to underline
that MCF10 and MCF7 cell counting started from day 7, after 24 h of ep-
ithelial cells addition into spinner flasks. Briefly, 200 µl of the same aliquot
was transferred to a cell culture dish (w/2 mm grid Nunc) for microcarrier
counting, after which the microcarrier suspension was placed in a new 2 ml
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tube and washed twice with PBS. To detach cells from microcarriers, µTP
were digested by collagenase A (Roche Life sciences, Italy) 60 min at 37
◦C, centrifuged 5 min at 2000 rpm, and incubated 5 min in Trypsin (Lonza,
Italy). The detached cells were then counted using a hemocytometer.
5.2.5 Masson’s Trichrome and confocal imaging
About 1 ml of NF/MCF10- and CAF/MCF7-µTP suspension was fixed in
a solution of 10% neutral buffered formalin for 1 h at RT, dehydrated in an
incremental series of ethanol (75%, 85%, 95% and 100% twice, each step 30
min at RT) treated with xylene and embedded in paraffin. Successively, the
samples were sectioned at a thickness of 7 µm. Masson’s trichrome (Sigma
Aldrich) staining was performed according to standard protocols. At last,
the sections were mounted with Histomount Mounting Solution (Bioptica)
on coverslips and the morphological features of µTP were observed with a
light microscope (Olympus, BX53).
For confocal imaging, NF/MCF10- and CAF/MCF7-µTP were fixed with
4% paraformaldehyde for 20 min and washed three times with PBS. After
nuclei staining with 1 µg/ml of 4’,6-diamidino-2-phenylindole (DAPI, Sigma-
Aldrich), fluorescence images were acquired (for DAPI λex = 700 nm and
λem = 425 ± 25 nm; for NF and CAF cells λex = 543 nm and λem =
590 ± 60 nm, water objective 40X with NA = 1.10). Two-photon excited
fluorescence has been used to induce Second Harmonic Generation (SHG)
and obtain high-resolution images of unstained collagen structures in µTP’
ECM (λex = 840 nm, λem = 420 ± 5 nm).
5.2.6 Immunofluorescence staining, imaging and quan-
tification
For immunofluorescence staining, formalin-fixed and paraffin embedded NF/
MCF10- and CAF/MCF7-µTP were unmasked by heat antigen retrieval pro-
tocol by citrate buffer; washed with PBS containing 0.2% Triton X-100,
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blocked with FBS and 5% BSA solution and incubated with primary anti-
body MMP-2 (1:200, Abcam UK). Secondary antibody incubation and DAPI
staining were performed, before closing the slices with glycerol solution. The
fluorescent images, previously acquired by using a multichanneled Leica TCS
SP5 II, were analyzed for semi-quantitative evaluation with ImageJ. After
threshold, the amount of signal was divided by the total number of cells
(previously obtained by counting their nuclei) in each image [114].
5.2.7 Gelatin zymography
Gelatin zymography was performed for both NF/MCF10- and CAF/MCF7-
µTP culture surnatans as follows: gel (SDS-PAGE, 10%) was copolymerised
with gelatin (0.1%) (Sigma-Aldrich). Electrophoresis was carried out using
minigel lab apparatus Mini Protean 3 (Biorad) at a constant voltage of 150 V
until the dye reached the bottom of the gel. Following electrophoresis, gel was
washed in renaturation buffer (2.5% Triton X-100 in 50 mM Tris- HCl pH 7.5)
for 1 h in an orbital shaker. Then the gel was incubated for 18 h at 37 ◦C in
incubation buffer (0.15 M NaCl, 10 mM CaCl2, 0.02% NaN3 in 50 mM Tris-
HCl pH 7.5). Gel was then stained with Coomassie blue and destained with
30% methanol and 10% acetic acid. Areas of enzymatic activity appeared as
clear bands over the dark background. Following zymogrphy, the degree of
gelatin digestion was quantified using Image J software and the image was
digitally inverted, so that the integration of bands was reported as positive
values. We reported the pixel intensity of the area of each gelatin-digested
band.
5.2.8 Nanoparticle preparation
In this work we tested two types of nanoparticles (NPs) named NP-PELGA-
TAP and PELGA-DOX. NP-PELGA-TAP is composed by poly(D,L-lactic-
co-glycolic acid) (PLGA) and polyethylene glycol (PEG) copolymer (namely
PELGA) blended with a Tumor-Activated Prodrug (TAP) composed of MMP-
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2 sensitive peptide bound to Doxorubicin (DOX) and to PLGA chain. The
second type of NPs is used as negative control because they lack of MMP-
sensitive linker. Both NPs were prepared by nanoprecipitation method ac-
cording to a previous published work [165]. Briefly, after synthesis of copoly-
mers and conjugates, 1 mg of PELGA and 1 mg of PLGA-TAP were dissolved
in 500 µl of acetone. After mixing, the solution was added dropwise with a
syringe pump into 12.5 ml of distillated water under magnetic stirring (600
rpm). The organic solvent was evaporated for 3 h and the obtained NP dis-
persion was sterilized using a 0.22 µm membrane filter. Finally, the reduction
in volume (1 ml) of the solution was obtained by serial centrifugations. Fur-
thermore, NP-PELGA-DOX were prepared with the same technique using 1
mg of PELGA-DOX and 1 mg of PELGA.
5.2.9 Drug treatment and confocal imaging
In order to have the same cell density, one NF/MCF10- and CAF/MCF7-
µTP were transferred into well of a round bottom 96 well plates. Both µTP
were treated with NP-PELGA-TAP and PELGA-DOX at 4 and 8 µg/ml
after dilution from a stock solution (40 µg/ml) for 48 and 72 h at 37 ◦C
in humidified atmosphere containing 5% CO2. One row of 96-wells plate
was used as control with 200 µL culture medium only. NF/MCF10- and
CAF/MCF7-µTP treated with NPs were washed three times with PBS and
fixed in 4% paraformaldehyde in PBS for 20 min. Cell nuclei were stained
with 1 µg/ml of DAPI (Sigma-Aldrich). DOX fluorescence was observed
under a confocal microscope (Leica) with excitation at 488 nm and emission
515 ± 15 nm, using a 40X water objective (NA = 1.10).
5.2.10 Cytotoxicity assay
After incubation time, 20 µL of 3-(4,5-dimethylthiazol-2-yl) - 2,5 - diphenyl-
tetrazolium bromide (MTT) solution (5 mg/ml) was added to each well, and
the plate was incubated for another 4 h, allowing the viable cells to reduce
130
the yellow MTT into dark-blue formazan crystals, which were dissolved into
100 µL of dimethyl sulfoxide (DMSO). The absorbance of individual well
was measured at 470 nm by a microplate reader (Enspire Multimode Plate
Reader PerkinElmer). All experiments were done in triplicates.
5.2.11 Statistical analysis
Differences between two or more groups were evaluated (pvalue < 0.05) us-
ing one-way analysis of variance (ANOVA). A Gaussian distribution for each
population was assumed. For pair-wise comparisons within each experimen-
tal group, Tukey’s post test was used.
5.3 Results
In this work we used a novel endogenous stimuli-responsive nanoparticle ther-
apy in normal and tumoral µTP. After characterization of heterotypic µTP
in terms of cell proliferation and ECM composition (collagen and MMP-2
expression), nanoparticle cytotoxicity response was investigated.
5.3.1 Cell proliferation in Healthy and Tumor Tissues
The healthy (NF/MCF10-µTP) and tumor (CAF/MCF7-µTP) µTP evolu-
tion was evaluated during 12 days of culture. In Fig. 5.1 A-B were reported
the cell number per µTP unit. In particular, NF and CAF cells started both
with 36 ± 5.57 cells at day 1 and after 12 days of culture they presented a
final cell number of 870 ± 129 and 1635 ± 136 respectively. At the same
time, for normal and tumor epithelial cell lines, the cell number increased
from 113 ± 45 and 248 ± 20 at day 7 (after 1 day of cell loading into spinner
flask) to 561 ± 113 and 2200 ± 306, respectively. These results highlighted
the greater proliferative capability of both tumor epithelial and stromal cells
compared to normal counterparts.
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Figure 5.1: Cell proliferation of CAF and MCF7 cells in tumor tissue (A)
and NF and MCF10 cells in healthy tissue (B).
5.3.2 ECM morphology and composition
From literature, it has been recognized the tumor microenvironment con-
tribute to resistance to molecular and nanoscale medicine [102]. Among
abnormal physiological characteristics, high stromal fraction in tumors lead
to diminished delivery as well as effectiveness of drugs [102]. For these rea-
sons, we verify if in our heterotypic µTP model, stromal cells are in the right
conditions to be able to produce a dense matrix structure, by performing
immunostaining and SHG analysis. Fig. 5.2 A-B reported the histological
sections stained by Masson Trichrome of normal and tumoral µTP. From im-
ages it was possible to distinguish the red signal related to the microbeads,
the purple signal due to the cells staining and blue signal of the endogenous
ECM. We also identify fibrillar collagen level from both tissues by SHG signal
(gray scale) as indicated in Fig. 5.2 C and D for healthy and tumor tissue,
respectively. In both cases the SHG signal was strong indicating a massive
collagen fibers deposition but with different organization. Taken together,
this data indicated the presence of endogenous ECM synthesized by stromal
cells NF and CAF in µTP configuration.
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Figure 5.2: Masson’s Trichrome staining in CAF/MCF7- (A) and
NF/MCF10-µTP (B); Scale bar = 100 µm. SHG images of CAF/MCF7-
(C) and NF/MCF10-µTP (D); Scale bar = 50 µm (cell nuclei in blue, CAF
and NF in red and SHG signal in gray).
5.3.3 MMP2 over-expression in Tumor Tissue
In this work, the expression and enzymatic activity of endogenous MMP-2
secreted by cells in NF/MCF10- and CAF/MCF7-µTP were verified by im-
munostaining and zymography analysis. From both techniques, high MMP-2
expression was detected in tumor tissue compared to normal one. Indeed,
as shown in Fig. 5.3 A-B, tumor tissue (Fig. 5.3 A) express greater level of
MMP-2 protein than normal tissue (Fig. 5.3 B). These findings are confirmed
by quantification analysis (p < 0.05, Fig. 5.3 C). Furthermore, zymography
results demonstrated that, although the inactive form of MMP-2 was greater
in normal tissue (p < 0.05), a higher amount of MMP-2 activity was found
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in CAF/MCF7-µTP compared to NF/MCF10-µTP (p < 0.05) (Fig. 5.3 D).
5.3.4 In vitro NP Imaging and Cytotoxicity
Having established that our tumor µTP model is a powerful tool for MMP-2-
mediated drug delivery via nanoparticles, we next evaluated the therapeutic
effectiveness of endogenous stimuli-responsive NP-PELGA-TAP. Therefore
NF/MCF10- and CAF/MCF7-µTP were exposed to NP-PELGA-TAP and
PELGA-DOX for 48 and 72 h. Figure 5.4 shows fluorescence images of tumor
and healthy tissue after both NPs treatment at 4 µg/ml for 72 h. As shown
in Fig. 5.4 A a diffused fluorescence was noticed around cells in CAF/MCF7-
Figure 5.3: MMP-2 levels in CAF/MCF7- and NF/MCF10-µTP. Im-
munofluorescence staining of MMP-2 protein (red) in CAF/MCF7- (A) and
NF/MCF10-µTP (B); quantification analysis of MMP-2 obtained from im-
munofluorescence (C); gelatin zymography showing the MMP-2 activity of
CAF/MCF7- and NF/MCF10-µTP (D).
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µTP incubated with NP-PELGA-TAP, indicating the release of free DOX.
On the other hand, a very low spotted fluorescence was observed when tumor
tissue is put in contact with NP-PELGA-DOX for 72 h (Fig. 5.4 B). More
interestingly, normal tissue have shown a low or not detectable fluorescence
of free DOX after both NPs type incubation (Fig. 5.4 C-D).
From brightfield images (Fig. 5.4 E-L) a reduction of µTP diameter was
identified in tumor tissue after both NPs treatment (Fig. 4F-G) compared
to control (Fig. 5.4 E). Indeed, outer cells detached from the µTP were
observed (indicated by white arrow, Fig. 5.4 F-G). Finally, the NF/MCF10-
µTP diameter remained roughly the same (Fig. 5.4 I-L) respect to control
(Fig. 5.4 H), indicating lower DOX release from NPs in healthy tissue.
We next investigated the cytotoxicity of NP-PELGA-TAP and PELGA-
DOX in NF/MCF10- and CAF/MCF7-µTP as a function of cell viability.
Fig. 5.5 shows cell viability percentage of treated µTP normalized to non-
Figure 5.4: Fluorescence distribution of DOX within CAF/MCF7-µTP upon
72 h incubation with PELGA-TAP (A) and PELGA-DOX (B) and within
NF/MCF10-µTP (C, D) at 4 µg/ml; scale bar = 50 µm. Brightfield images of
CAF/MCF7- (E-G) and NF/MCF10-µTP (H-L) after 72h of PELGA-TAP
and PELGA-DOX treatment at 4 µg/ml (E-H controls); scale bar = 200 µm
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treated µTP as a function of drug concentration after 48 and 72 h of treat-
ment. For tumor tissue, it was observed an increase in cytotoxic response
with incubation time raise (dark gray bar in Fig. 5.5 A-B) for both NPs
treatments. However, only after NP-PELGA-TAP treatment, CAF/MCF7-
µTP achieved the IC50 value at 4 µg/ml for 72h. This value indicates the
concentration at which 50% of cellular activity is inhibited. On the contrary,
no inhibition effect in cell proliferation was found in NF/MCF10-µTP after
both NPs treatment (Fig. 5.5 C-D). These results demonstrate the selective
cytotoxic effect of MMP-2-stimuli responsive NP-PELGA-TAP.
Figure 5.5: Cytotoxicity assay in tumor CAF/MCF7-µTP after treatment
with NP-PELGA-TAP (A) and PELGA-DOX (B) and in healthy tissue
NF/MCF7-µTP after NP-PELGA-TAP (C) and PELGA-DOX (D) treat-
ment at 4 and 8 µg/ml for 48 and 72 h.
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5.3.5 Discussions
In the present study we apply endogenous stimuli responsive nanoparticles to
normal and tumroal heterotypic µTP composed of both epithelial and stro-
mal cells. This heterotypic model better recapitulates cell microenvironment
compared to other more used 3D cell culture like spheroids or cells embed-
ded in natural or synthetic gels. In particular the tumor microenvironment
is composed not only by tumor cell aggregates but also contains other cells
of stroma milieu like CAF that contribute to hinder drug distribution [14].
Therefore it is important to incorporate stromal elements in in vitro tumor
tissue models, as we did, introducing CAF cells that are able to produce and
synthesize ECM. The interaction between cells and extracellular matrix plays
a pivotal role in cellular behaviors such as proliferation and migration. In
fact as demonstrated by growth curves, tumor epithelial (MCF7) and stro-
mal (CAF) cells have greater proliferative capability due to tumor nature
compared to normal counterparts (MCF10 and NF, respectively). Therefore
it should be emphasized the presence of endogenous ECM as shown by Mas-
son’s Trichrome staining and SHG signal, demonstrating a more complex in
vitro 3D tissue model able to mimic tumor microenvironment seen in vivo.
On the other side, nanoparticles as drug delivery carriers have received a lot
of attention in the last decades. Their success is mainly due to the improved
accumulation of active drugs at disease sites, reducing systemic toxicity in
healthy neighbors zones. Recently, stimuli-responsive nanoparticles has been
emerging as the most promising strategy [177]. This approach is able to fur-
ther increase tumor specificity and effectiveness of nanoparticles, releasing
high concentrations of cytotoxic drugs in presence of cellular/extracellular
stimuli of chemical, biochemical or physical origin. Some of these stimuli
are naturally occurring in vivo like MMP-2 overexpression in tumor tissues
[178]. Many works are presented focusing on the development of NPs re-
sponsive to MMP-2 presence. Especially in a recent work, Cantisani et al.
(2015), exploited a strategy of drug targeting of tumors using nanoparticles
that release cytotoxic drugs in response to specific physiological variations
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typical of tumor tissue [165]. It is well-known that MMP-2 are overexpressed
in most tumors, like breast cancer [179]. Because MMP-2 expression has a
role in tumor progression and invasion, this feature was chosen as a trigger
for the release of drug payload. Compared to other previous works [180], in
this case drug release is mediated by MMP-2 cleavage in the extracellular
space not by cellular uptake. In this work we combine the use of MMP-2
responsive nanoparticles to µTP for a more valuable drug testing. We pre-
viously verify if in our tissue model a MMP-2 overexpression occurred at
extracellular level. As demonstrated by immunofluorescence signal quantifi-
cation and by zymography analysis, MMP-2 expression in CAF/MCF7-µTP
was greater than NF/MCF10-µTP. Consequently, the higher MMP-2 level
in CAF/MCF7-µTP efficiently cleaved the peptide drug-polymer bond, al-
lowing the DOX liberation in the extracellular space. In this way it was
possible to obtain a significantly reduction of cell viability compared to NP
control (PELGA-DOX) without the MMP-sensitive linker. In the last case,
the reduced cytotoxic effect was due to the covalent bound of DOX to NPs
that not promoting the leakage of drug. These results are in accordance
with a previous work [165] where the disaggregation of tumor spheroids is
reached after 48 h of incubation. In our case, the cytotoxic effect was reached
later, after 72 h of NP treatments. The reason is mainly due to the differ-
ence in tumor configuration. In our work the tumor tissue is heterotypic,
composed not only by tumor tissue but also by stroma. Therefore the pres-
ence of stromal component contributes to drug resistance [181] delaying the
therapeutic effects. Furthermore, NP-PELGA-TAP specificity was demon-
strated in healthy tissue in which the low presence of extracellular MMP-2
was detected. Consequently not significantly cytotoxic effect was found in
NF/MCF10-µTP. On the contrary, in the presence of MMP-2 overexpression,
stimuli-responsive NPs are able to favor DOX penetration within tumor ma-
trix after enzymatic cleavage. In this way a reduction of drug dose as well as
an improved therapeutic efficacy can be reached.
In summary, this study shows the feasibility of MMP-2-mediated drug
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release in tumor breast tissue that closely reflects the human pathophysiology.
In this way, DOX despite its high cytotoxicity when was in the free state,
can be safely carried through healthy tissues. The release of the drug and
therefore its desired cytotoxic action towards tumor cells could be induced
only in the presence of MMP-2. As this model closely reflects the human
pathophysiology, we believe that therapeutic strategies that are confirmed
in this model are more likely to translate to humans, avoiding the use of
time-consuming xenograft models.
5.4 Conclusions
In this work a recently validated formulation of endogenous stimuli-responsive
nanoparticles and the 3D µTP approach was combined. In order to have a
better pre-clinical evaluation of anticancer drugs, the proposed heterotypic
3D µTP model closely resembles in vivo tumor microenvironment due to
the presence of high proliferative tumor cell capability and dense matrix
structure. In this way, the cytotoxic results obtained after NP-PELGA-TAP
treatment, accurately forecast tumor’s in vivo response. Furthermore, the
integration of prodrug concept and endogenous stimuli in nanoparticles, lead
the accumulation of cytotoxic drug in the extracellular space of tumor, re-
sulting in enhanced anticancer activity and reducing undesirable side effects
on healthy tissues.
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